CN115368246A - 一类精氨酸甲基转移酶抑制剂及其用途 - Google Patents
一类精氨酸甲基转移酶抑制剂及其用途 Download PDFInfo
- Publication number
- CN115368246A CN115368246A CN202110875453.9A CN202110875453A CN115368246A CN 115368246 A CN115368246 A CN 115368246A CN 202110875453 A CN202110875453 A CN 202110875453A CN 115368246 A CN115368246 A CN 115368246A
- Authority
- CN
- China
- Prior art keywords
- unsubstituted
- substituted
- ring
- alkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000757232 Homo sapiens Protein arginine N-methyltransferase 2 Proteins 0.000 title abstract description 5
- 229940123379 Methyltransferase inhibitor Drugs 0.000 title abstract description 3
- 102000046485 human PRMT2 Human genes 0.000 title abstract description 3
- 239000003697 methyltransferase inhibitor Substances 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 101710084434 Protein arginine N-methyltransferase 1 Proteins 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- -1 cyano, amino, nitro, hydroxy, mercapto Chemical class 0.000 claims description 119
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 112
- 125000003118 aryl group Chemical group 0.000 claims description 80
- 125000000623 heterocyclic group Chemical group 0.000 claims description 65
- 229910052757 nitrogen Chemical group 0.000 claims description 64
- 229920006395 saturated elastomer Polymers 0.000 claims description 44
- 125000002837 carbocyclic group Chemical group 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 41
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 125000005842 heteroatom Chemical group 0.000 claims description 36
- 229910052760 oxygen Inorganic materials 0.000 claims description 36
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 34
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 34
- 239000001301 oxygen Substances 0.000 claims description 34
- 229910052717 sulfur Inorganic materials 0.000 claims description 34
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 32
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 32
- 239000011593 sulfur Chemical group 0.000 claims description 32
- 125000006413 ring segment Chemical group 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 125000004104 aryloxy group Chemical group 0.000 claims description 16
- 125000004185 ester group Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000001769 aryl amino group Chemical group 0.000 claims description 2
- 150000001556 benzimidazoles Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000002473 indoazoles Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229910052722 tritium Inorganic materials 0.000 claims description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 16
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 228
- 238000006243 chemical reaction Methods 0.000 description 164
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 102
- 239000000243 solution Substances 0.000 description 85
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 82
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 78
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 61
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 55
- 230000002829 reductive effect Effects 0.000 description 52
- 238000005481 NMR spectroscopy Methods 0.000 description 42
- 239000003208 petroleum Substances 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- 230000015572 biosynthetic process Effects 0.000 description 37
- 238000004440 column chromatography Methods 0.000 description 35
- 239000007787 solid Substances 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 239000000543 intermediate Substances 0.000 description 32
- 239000000377 silicon dioxide Substances 0.000 description 31
- 239000000706 filtrate Substances 0.000 description 29
- 238000003786 synthesis reaction Methods 0.000 description 29
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 26
- 235000019341 magnesium sulphate Nutrition 0.000 description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 25
- 239000012074 organic phase Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 24
- 238000000746 purification Methods 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
- 150000001299 aldehydes Chemical class 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 239000012043 crude product Substances 0.000 description 17
- 238000004809 thin layer chromatography Methods 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000001514 detection method Methods 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 12
- 101000757216 Homo sapiens Protein arginine N-methyltransferase 1 Proteins 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 102100022985 Protein arginine N-methyltransferase 1 Human genes 0.000 description 11
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- DEXPYFMTTXKXLN-UHFFFAOYSA-N CC(C)(C)OC(C1=CC=C2N(C3OCCCC3)N=CC2=C1Br)=O Chemical compound CC(C)(C)OC(C1=CC=C2N(C3OCCCC3)N=CC2=C1Br)=O DEXPYFMTTXKXLN-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 101000924541 Homo sapiens Protein arginine N-methyltransferase 3 Proteins 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 102100034603 Protein arginine N-methyltransferase 3 Human genes 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 6
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- AJEQMRSFVJOSSV-UHFFFAOYSA-N 6-[bis[(4-methoxyphenyl)methyl]amino]-2-chloropyridine-3-carbaldehyde Chemical compound C1=CC(OC)=CC=C1CN(C=1N=C(Cl)C(C=O)=CC=1)CC1=CC=C(OC)C=C1 AJEQMRSFVJOSSV-UHFFFAOYSA-N 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 5
- 229960001570 ademetionine Drugs 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 229910000160 potassium phosphate Inorganic materials 0.000 description 5
- 235000011009 potassium phosphates Nutrition 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- MCYAACAGIQVDMR-UHFFFAOYSA-N tert-butyl 4-bromo-1h-indazole-5-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=C2NN=CC2=C1Br MCYAACAGIQVDMR-UHFFFAOYSA-N 0.000 description 5
- DFVRUHANEXOZGT-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-(methylamino)ethyl]carbamate Chemical compound CNCCN(C)C(=O)OC(C)(C)C DFVRUHANEXOZGT-UHFFFAOYSA-N 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- JTEZQWOKRHOKDG-UHFFFAOYSA-N 1,2-dibromo-4,5-difluorobenzene Chemical compound FC1=CC(Br)=C(Br)C=C1F JTEZQWOKRHOKDG-UHFFFAOYSA-N 0.000 description 4
- GVPYLQUBHKXFJP-UHFFFAOYSA-N 1-(3-methylphenyl)piperidin-4-one Chemical compound CC1=CC=CC(N2CCC(=O)CC2)=C1 GVPYLQUBHKXFJP-UHFFFAOYSA-N 0.000 description 4
- HSLSPVXWVJEEHL-UHFFFAOYSA-N CC(C)(C)OC(C1=CC=C2N(C3OCCCC3)N=CC2=C1C(CC1)CCN1C1=CC=CC(C)=C1)=O Chemical compound CC(C)(C)OC(C1=CC=C2N(C3OCCCC3)N=CC2=C1C(CC1)CCN1C1=CC=CC(C)=C1)=O HSLSPVXWVJEEHL-UHFFFAOYSA-N 0.000 description 4
- UFLXTIYNBBBBIN-UHFFFAOYSA-N CC1=CC(N(CC2)CC=C2C2=NC(N(CC(C=C3)=CC=C3OC)CC(C=C3)=CC=C3OC)=CC=C2C=O)=CC=C1 Chemical compound CC1=CC(N(CC2)CC=C2C2=NC(N(CC(C=C3)=CC=C3OC)CC(C=C3)=CC=C3OC)=CC=C2C=O)=CC=C1 UFLXTIYNBBBBIN-UHFFFAOYSA-N 0.000 description 4
- WNURPMZXEBWFOB-UHFFFAOYSA-N CC1=CC(N(CC2)CCC2C2=C(C=NN3C4OCCCC4)C3=CC=C2C=O)=CC=C1 Chemical compound CC1=CC(N(CC2)CCC2C2=C(C=NN3C4OCCCC4)C3=CC=C2C=O)=CC=C1 WNURPMZXEBWFOB-UHFFFAOYSA-N 0.000 description 4
- SWMSGIWOWWZZGV-UHFFFAOYSA-N CC1=CC(N(CC2)CCC2C2=C(C=NN3C4OCCCC4)C3=CC=C2CO)=CC=C1 Chemical compound CC1=CC(N(CC2)CCC2C2=C(C=NN3C4OCCCC4)C3=CC=C2CO)=CC=C1 SWMSGIWOWWZZGV-UHFFFAOYSA-N 0.000 description 4
- UGKSRDIECPKMNQ-UHFFFAOYSA-N CC1=CC(N(CC2)CCC2C2=C(C=O)C=CC(N(CC(C=C3)=CC=C3OC)CC(C=C3)=CC=C3OC)=N2)=CC=C1 Chemical compound CC1=CC(N(CC2)CCC2C2=C(C=O)C=CC(N(CC(C=C3)=CC=C3OC)CC(C=C3)=CC=C3OC)=N2)=CC=C1 UGKSRDIECPKMNQ-UHFFFAOYSA-N 0.000 description 4
- NSHRLXCGBUEGAH-UHFFFAOYSA-N CC1=CC(N(CC2)CCC2C2=NC(N(CC(C=C3)=CC=C3OC)CC(C=C3)=CC=C3OC)=CC=C2CO)=CC=C1 Chemical compound CC1=CC(N(CC2)CCC2C2=NC(N(CC(C=C3)=CC=C3OC)CC(C=C3)=CC=C3OC)=CC=C2CO)=CC=C1 NSHRLXCGBUEGAH-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- 102100025210 Histone-arginine methyltransferase CARM1 Human genes 0.000 description 4
- 101000775582 Homo sapiens Protein arginine N-methyltransferase 6 Proteins 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- VYSFKFANNSOUPI-UHFFFAOYSA-N OCCC(C=C1F)=C(CCO)C=C1F Chemical compound OCCC(C=C1F)=C(CCO)C=C1F VYSFKFANNSOUPI-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 102000003708 Protein arginine N-methyltransferase Human genes 0.000 description 4
- 108020000912 Protein arginine N-methyltransferase Proteins 0.000 description 4
- 102100032140 Protein arginine N-methyltransferase 6 Human genes 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 108010030886 coactivator-associated arginine methyltransferase 1 Proteins 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- NBRBTTQLJTWGOH-UHFFFAOYSA-N tert-butyl 2-bromo-4-fluoro-3-formylbenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(F)C(C=O)=C1Br NBRBTTQLJTWGOH-UHFFFAOYSA-N 0.000 description 4
- NCGLBILYMNWPMU-UHFFFAOYSA-N tert-butyl 2-bromo-4-fluorobenzoate Chemical compound CC(C)(C)OC(=O)C1=CC=C(F)C=C1Br NCGLBILYMNWPMU-UHFFFAOYSA-N 0.000 description 4
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- PSZQXRWMFYMVIE-UHFFFAOYSA-N CC(C)(C)OC(C1=CC=C2N(C3OCCCC3)N=CC2=C1C(CC1)=CCN1C1=CC=CC(C)=C1)=O Chemical compound CC(C)(C)OC(C1=CC=C2N(C3OCCCC3)N=CC2=C1C(CC1)=CCN1C1=CC=CC(C)=C1)=O PSZQXRWMFYMVIE-UHFFFAOYSA-N 0.000 description 3
- NQQSZFQEKDPJMU-UHFFFAOYSA-N CC1(C)OB(C(CC2)=CCN2C2=CC=CC(C)=C2)OC1(C)C Chemical compound CC1(C)OB(C(CC2)=CCN2C2=CC=CC(C)=C2)OC1(C)C NQQSZFQEKDPJMU-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- COERJHDMQUPDCV-UHFFFAOYSA-N [K].FB(F)F Chemical compound [K].FB(F)F COERJHDMQUPDCV-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001483 arginine derivatives Chemical class 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HWTMRGXKSANEDO-UHFFFAOYSA-N 2,6-dichloropyridine-3-carbaldehyde Chemical compound ClC1=CC=C(C=O)C(Cl)=N1 HWTMRGXKSANEDO-UHFFFAOYSA-N 0.000 description 2
- GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 2
- FWPFXBANOKKNBR-UHFFFAOYSA-N 2-[2-(cyanomethyl)phenyl]acetonitrile Chemical compound N#CCC1=CC=CC=C1CC#N FWPFXBANOKKNBR-UHFFFAOYSA-N 0.000 description 2
- RRKPMLZRLKTDQV-UHFFFAOYSA-N 2-bromo-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1Br RRKPMLZRLKTDQV-UHFFFAOYSA-N 0.000 description 2
- SXDBLLSINHOGPK-UHFFFAOYSA-N 2-chloro-6-methylpyridine-3-carbaldehyde Chemical compound CC1=CC=C(C=O)C(Cl)=N1 SXDBLLSINHOGPK-UHFFFAOYSA-N 0.000 description 2
- RMHQDKYZXJVCME-UHFFFAOYSA-N 2-pyridin-4-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=NC=C1 RMHQDKYZXJVCME-UHFFFAOYSA-N 0.000 description 2
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 201000002847 Cowden syndrome Diseases 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 101000693024 Homo sapiens Protein arginine N-methyltransferase 7 Proteins 0.000 description 2
- 101000796142 Homo sapiens Protein arginine N-methyltransferase 8 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100022988 Protein arginine N-methyltransferase 2 Human genes 0.000 description 2
- 102100026297 Protein arginine N-methyltransferase 7 Human genes 0.000 description 2
- 102100031365 Protein arginine N-methyltransferase 8 Human genes 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000003843 furanosyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000004262 preparative liquid chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 2
- 125000003132 pyranosyl group Chemical group 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical class CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 description 1
- QJIMTLTYXBDJFC-UHFFFAOYSA-N (4-methylphenyl)-diphenylphosphane Chemical compound C1=CC(C)=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJIMTLTYXBDJFC-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- BNGIFLFGYVMNLE-UHFFFAOYSA-N 1-(3-methylphenyl)-3,6-dihydro-2h-pyridine Chemical compound CC1=CC=CC(N2CC=CCC2)=C1 BNGIFLFGYVMNLE-UHFFFAOYSA-N 0.000 description 1
- HBKPDEWGANZHJO-UHFFFAOYSA-N 1-(4-methoxyphenyl)-n-[(4-methoxyphenyl)methyl]methanamine Chemical compound C1=CC(OC)=CC=C1CNCC1=CC=C(OC)C=C1 HBKPDEWGANZHJO-UHFFFAOYSA-N 0.000 description 1
- RDHNFSNXWLWMIX-UHFFFAOYSA-N 1-n,2-n-dimethylpropane-1,2-diamine Chemical compound CNCC(C)NC RDHNFSNXWLWMIX-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N 2-azaniumyl-5-[(n'-methylcarbamimidoyl)amino]pentanoate Chemical compound CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- TWBPWBPGNQWFSJ-UHFFFAOYSA-N 2-phenylaniline Chemical group NC1=CC=CC=C1C1=CC=CC=C1 TWBPWBPGNQWFSJ-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ASZZHBXPMOVHCU-UHFFFAOYSA-N 3,9-diazaspiro[5.5]undecane-2,4-dione Chemical compound C1C(=O)NC(=O)CC11CCNCC1 ASZZHBXPMOVHCU-UHFFFAOYSA-N 0.000 description 1
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 description 1
- OZIMPUNGBUYCSP-UHFFFAOYSA-N 3-fluoropyridine-2-carbaldehyde Chemical compound FC1=CC=CN=C1C=O OZIMPUNGBUYCSP-UHFFFAOYSA-N 0.000 description 1
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VZCCTDLWCKUBGD-UHFFFAOYSA-N 8-[[4-(dimethylamino)phenyl]diazenyl]-10-phenylphenazin-10-ium-2-amine;chloride Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1N=NC1=CC=C(N=C2C(C=C(N)C=C2)=[N+]2C=3C=CC=CC=3)C2=C1 VZCCTDLWCKUBGD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000012815 AlphaLISA Methods 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- LETPTXWEWURQLT-UHFFFAOYSA-N C1(CCCCC1)P(C1(C(=C(C=C(C1)C(C)C)C(C)C)C1=CC=CC=C1)C(C)C)C1CCCCC1.[Cl] Chemical group C1(CCCCC1)P(C1(C(=C(C=C(C1)C(C)C)C(C)C)C1=CC=CC=C1)C(C)C)C1CCCCC1.[Cl] LETPTXWEWURQLT-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- XYYARMOJXIDCJM-UHFFFAOYSA-N CC(CNC)NCC1=CC=C(C)N=C1C(CC1)CCN1C1=CC=CC(C)=C1 Chemical compound CC(CNC)NCC1=CC=C(C)N=C1C(CC1)CCN1C1=CC=CC(C)=C1 XYYARMOJXIDCJM-UHFFFAOYSA-N 0.000 description 1
- GZYDUYJDWVBWJR-UHFFFAOYSA-N CC1=CC(N(CC2)CCC2C2=NC(N)=CC=C2CC(CNC)NC)=CC=C1 Chemical compound CC1=CC(N(CC2)CCC2C2=NC(N)=CC=C2CC(CNC)NC)=CC=C1 GZYDUYJDWVBWJR-UHFFFAOYSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- 101100216105 Caenorhabditis elegans prmt-1 gene Proteins 0.000 description 1
- 101100434927 Caenorhabditis elegans prmt-5 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 208000012609 Cowden disease Diseases 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101150096028 Prmt7 gene Proteins 0.000 description 1
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 description 1
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- 101000985737 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Protein arginine N-methyltransferase HSL7 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101000651946 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein arginine N-methyltransferase skb1 Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 239000012391 XPhos Pd G2 Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- ULLRFUHXXXZSCT-UHFFFAOYSA-N [O].[O].Cl Chemical compound [O].[O].Cl ULLRFUHXXXZSCT-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006217 arginine-methylation Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000000638 benzylaminocarbonyl group Chemical group C(C1=CC=CC=C1)NC(=O)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- HTJWUNNIRKDDIV-UHFFFAOYSA-N bis(1-adamantyl)-butylphosphane Chemical compound C1C(C2)CC(C3)CC2CC13P(CCCC)C1(C2)CC(C3)CC2CC3C1 HTJWUNNIRKDDIV-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000013078 crystal Chemical group 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000005640 glucopyranosyl group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- BICAGYDGRXJYGD-UHFFFAOYSA-N hydrobromide;hydrochloride Chemical compound Cl.Br BICAGYDGRXJYGD-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- GQJCAQADCPTHKN-UHFFFAOYSA-N methyl 2,2-difluoro-2-fluorosulfonylacetate Chemical compound COC(=O)C(F)(F)S(F)(=O)=O GQJCAQADCPTHKN-UHFFFAOYSA-N 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 101150097768 prmt5 gene Proteins 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/52—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
本发明提供了一类精氨酸甲基转移酶抑制剂及其用途,具体地,本发明提供了一类可以用作I型PRMT抑制剂的化合物、其制备方法以及在相关疾病治疗中的应用。所述的化合物具有式I所示的结构。
Description
技术领域
本发明涉及药物化学和医药领域,具体涉及一类I型PRMT抑制剂化合物、其制备方法以及在疾病治疗领域的应用。
背景技术
蛋白质精氨酸甲基化是在细胞质和细胞核中广泛存在的高丰度翻译后修饰方式,蛋白质精氨酸甲基转移酶(PRMTs)家族是参与蛋白质精氨酸甲基化过程的关键酶,其主要以S-腺苷甲硫氨酸(SAM)为甲基供体,甲基化修饰蛋白质精氨酸侧链的氮原子,生成S-腺苷同型半胱氨酸和甲基精氨酸。PRMTs家族包含9种PRMT。根据催化反应类型不同,可将PRMT分为Ⅰ型(PRMT1\PRMT2\PRMT3\PRMT4\PRMT6\PRMT8)、Ⅱ型(PRMT5\PRMT9)和Ⅲ型(PRMT7)。Ⅰ型PRMT负责非对称性双甲基化精氨酸(ADMA)、Ⅱ型PRMT负责对称性双甲基化精氨酸(SDMA)、Ⅲ型PRMT负责单甲基化精氨酸(MMA)。
目前已有多篇文献证实Ⅰ型PRMT的表达异常与多种疾病的发生发展密切相关。如PRMT1被发现在白血病、肺癌、肝癌、胃癌、结肠癌、乳腺癌、胰腺癌、头颈部肿瘤、前列腺癌、膀胱癌等癌症中发挥致癌功能。在恶性胶质瘤中,发现PRMT2在蛋白水平上高表达,并且与不良预后密切相关。在70%的急性髓性白血病(AML)病人中,都可观察到PRMT4的表达有至少两倍的升高。PRMT6被发现在52.6%的胃癌细胞中高表达,并且其表达量与其底物的修饰水平呈显著正相关。同时,由于Ⅰ型PRMT主要负责催化精氨酸不对称二甲基化,体内不对称二甲基化水平的改变与心血管疾病、糖尿病、肾功能衰竭、哮喘和慢性非阻塞疾病有着密不可分的关系。因此,可以说Ⅰ型PRMT的异常表达与多种疾病的发生发展相关。综上所述,开发新型PRMT抑制剂分子具有重要的意义。
发明内容
本发明的目的是提供一种新型PRMT抑制剂分子。
本发明的第一方面,提供了一种如下式I所示的化合物,或其药学上可接受的盐或氘代产物:
X1、X2、X3和X4各自独立地选自下组:CR、NR或N;虚线为化学键或无;
A环选自下组:取代或未取代的饱和或部分不饱和(非芳香)的4-8元碳环、取代或未取代的饱和或部分不饱和(非芳香)的4-8元杂环;
B环选自下组:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳环、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的3-12元的杂环、取代或未取代的-C1-C6烷基-6-10元芳基、取代或未取代的C3-C12碳环、取代或未取代的C2-C10酰基、取代或未取代的C2-C10酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
m和n各自独立地选自下组:0、1、2、3、4、5或6;
L选自下组:化学键,或-O-、-(CHR6)p-、-CHR6-O-、-CHR6-C(O)-、羰基、S、-NH-、-NHC(O)-、-NHS(O)2-、-NHC(O)NH-、-NHC(S)NH-、-COO-、-O-S(O)2-、-COO-CH2-、-C(O)CH2-、-S(O)2-,或L不存在;
p选自下组:1、2或3;
R1和R2各自独立地选自下组:H、取代或未取代的C1-C6烷基、取代或未取代的C3-C6环烷基;
R3为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C12碳环、取代或未取代的C2-C10酰基、取代或未取代的C2-C10酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
R为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的4-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C12碳环、取代或未取代的C2-C10酰基、取代或未取代的C2-C10酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
或两个位于相邻环原子上的R与其相连的环原子共同构成取代或未取代的5-11元碳环或杂环,所述的环为部分不饱和或饱和的;较佳地,所述的碳环或杂环为5-9元碳环或杂环,更优选为5-7元碳环或杂环(所述的碳环或杂环为饱和、部分不饱和或芳香性的);
R4为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C12碳环、取代或未取代的C2-C10酰基、取代或未取代的C2-C10酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
或两个位于相同或相邻环原子上的R4与其相连的环原子共同构成取代或未取代的3-11元碳环或杂环,所述的环为部分不饱和环、饱和环或芳香性环;
R6为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、酰基磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基;
除非特别说明,上述各式中,所述的取代指对应基团上的氢原子被一个或多个选自下组的取代基所取代:氘、氚、卤素、羟基、羧基、巯基、苄基、氧(=O)、C1-C12烷氧基羰基、C1-C6醛基、氨基、C1-C6酰胺基、硝基、氰基、未取代或卤代的C1-C6烷基、C2-C10烯基、C1-C6烷氧基、C1-C6烷基-胺基、C1-C6烷基-S-、C6-C10芳基、五元或六元杂芳基、五元或六元非芳香性杂环基、-O-(C6-C10芳基)、-O-(五元或六元杂芳基)、-NH-(C6-C10芳基)、-NH-(五元或六元杂芳基)、C1-C12烷氨基羰基、未取代或卤代的C2-C10酰基、磺酰基(-SO2-OH)、磷酰基(-PO3-OH)、未取代或卤代的C1-C4烷基-S(O)2-、未取代或卤代C1-C4烷基-SO-;各式中,杂环或杂芳环中具有1-3个选自下组的杂原子:N、S或O;
所述的芳香环、芳香性环或芳香体系包括芳香环的常规互变异构体,如吡啶酮、苯并咪唑、苯并吡唑等。
在另一优选例中,X1、X2、X3和X4中至少一个为N。
在另一优选例中,当B环为H时,所述的m为2、3、4、5或6;且至少两个相同或相邻环原子上的R4与其相连的环原子共同构成取代或未取代的5-11元碳环或杂环(所述的环为部分不饱和环、饱和环或芳香性环)。
在另一优选例中,所述的R3为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-10元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;和/或
R为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-10元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;或两个位于相邻环原子上的R与其相连的碳原子共同构成取代或未取代的5-9元碳环或杂环,所述的环为部分不饱和、饱和或芳香性的;和/或
在另一优选例中,R4为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-7元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C10酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;或两个位于相邻环原子上的R4与其相连的碳原子共同构成取代或未取代的5-9元碳环或杂环,所述的环为部分不饱和或饱和的。
在另一优选例中,所述的B环选自下组:H,或取代或未取代的苯基、取代或未取代的5-10元杂芳环、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的3-12元的杂环、取代或未取代的C3-C12碳环。
在另一优选例中,其特征在于,所述的R3为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-10元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;和/或
R为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;或两个位于相邻环原子上的R与其相连的环原子共同构成取代或未取代的5-7元碳环或杂环;和/或
R4为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C10酯基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;或两个位于相邻环原子上的R4与其相连的碳原子共同构成取代或未取代的5-9元碳环或杂环,所述的环为部分不饱和或饱和的。
在另一优选例中,所述的B环选自下组:取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的4-12元的杂环、取代或未取代的C3-C12碳环。
在另一优选例中,所述的A环选自下组:
或所述的A环与2个R4共同构成选自下组的基团:
在另一优选例中,所述的A环为取代或未取代的选自下组的基团:
或所述的A环与2个R4共同构成选自取代或未取代的下组的基团:
在另一优选例中,所述的化合物具有如下式II所示的结构:
在另一优选例中,所述的化合物具有如下式III所示的结构:
其中,
A环选自下组:取代或未取代的饱和或部分不饱和(非芳香)的4-8元碳环、取代或未取代的饱和或部分不饱和(非芳香)的4-8元杂环;
B环选自下组:取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的3-12元的杂环、取代或未取代的C3-C12碳环;
较佳地,R3为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
较佳地,R4为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-7元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-。
在另一优选例中,所述的化合物具有如下式IV所示的结构:
其中,
A1环选自下组:取代或未取代的饱和或部分不饱和(非芳香)的5-8元碳环、取代或未取代的饱和或部分不饱和(非芳香)的5-8元杂环;
A2环选自下组:取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的C3-C12碳环;且A2环和A1环稠合;
A3环和A4环各自独立地选自下组:取代或未取代的饱和或部分不饱和(非芳香)的5-8元碳环、取代或未取代的饱和或部分不饱和(非芳香)的3-8元杂环;
m为0、1、2、3或4;R5选自下组:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C6-C10芳氧基或杂芳氧基、取代或未取代的C6-C10芳胺基或杂芳胺基,取代或未取代的C1-C6酰胺基、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;且R5可以位于A1环、A2环、A3环或A4环上。
在另一优选例中,所述的化合物具有如下式V或式VI所示的结构:
其中,C环为取代或未取代的苯基、取代或未取代的5-7元杂环基、或取代或未取代的5-6元杂芳基;
A环选自下组:取代或未取代的饱和或部分不饱和(非芳香)的5-6元碳环、取代或未取代的饱和或部分不饱和(非芳香)的4-8元杂环;
B环选自下组:取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的4-12元的杂环、取代或未取代的C3-C12碳环;
较佳地,R3为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
较佳地,R4为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-7元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-。
在另一优选例中,所述的C环选自下组:苯环、5-7元杂芳环、5-7元饱和或部分不饱和杂环。
在另一优选例中,所述的式I化合物具有如下式所示的结构:
XX5、X6、X7和X8各自独立地选自下组:C(R)2、NR、CR或N;虚线为化学键或无。
在另一优选例中,所述的化合物选自化合物P001-P334。
本发明的第二方面,提供了一种药物组合物,所述的药物组合物含有治疗有效量的如本发明第一方面所述的式I化合物、或其可药用的盐,以及一种或多种可药用的载体、赋形剂、佐剂、辅料和/或稀释剂。
本发明的第三方面,提供了一种如本发明第一方面所述的式I化合物、或其可药用盐在制备治疗或预防与PRMT相关的疾病的药物组合物中的用途;较佳地,所述的PRMT为I型PRMT。
在另一优选例中,所述的疾病选自下组:肿瘤、心血管疾病、神经退行性疾病、疟疾、艾滋病、痛风、糖尿病、肾功能衰竭、慢性肺部疾病、眼咽型肌营养不良、可卡因成瘾、肺动脉高压疾病、肌萎缩侧索硬化症、酒精性肝硬化。
在另一优选例中,所述的肿瘤选自脑癌、成胶质细胞瘤、白血病、淋巴瘤、Bannayan-Zonana综合征、考登病、Lhermitte-Duclos病、乳腺癌、维尔姆斯瘤、尤因肉瘤、横纹肌肉瘤、室管膜瘤、成神经管细胞瘤、结肠癌、胃癌、膀肤癌、头颈癌、肾癌、肺癌、肝癌、黑素瘤、卵巢癌、胰腺癌、前列腺癌、肉瘤、骨肉瘤、骨巨细胞瘤和甲状腺癌中的任一种。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
具体实施方式
本发明人通过广泛而深入的研究,首次意外地发现一类具有PRMT抑制作用的化合物。在此基础上完成了本发明。
术语
在本发明中,所述卤素为F、Cl、Br或I。
在本发明中,除非特别指出,所用术语具有本领域技术人员公知的一般含义。本发明中,如果没有特别指明,所有化学式意在涵盖可能的任何光学或几何异构体(例如R型、S型或外消旋体,或者烯烃的顺反异构体等)。
在本发明中,术语“C1-C6烷基”是指具有1至6个碳原子的直链或支链烷基,非限制性地包括甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基和已基等;优选乙基、丙基、异丙基、丁基、异丁基、仲丁基和叔丁基。
在本发明中,术语“C1-C6烷氧基”是指具有1至6个碳原子的直链或支链烷氧基,非限制性地包括甲氧基、乙氧基、丙氧基、异丙氧基和丁氧基等。
在本发明中,术语“C2-C6烯基”是指具有2至6个碳原子的含有一个双键的直链或支链烯基,非限制性地包括乙烯基、丙烯基、丁烯基、异丁烯基、戊烯基和己烯基等。
在本发明中,术语“C2-C6炔基”是指具有2至6个碳原子的含有一个三键的直链或支链炔基,非限制性地包括乙炔基、丙炔基、丁炔基、异丁炔基、戊炔基和己炔基等。
在本发明中,术语“C3-C10环烷基”是指在环上具有3至10个碳原子的环状烷基,非限制性地包括环丙基、环丁基、环戊基、环己基、环庚基、环辛基和环癸基等。术语“C3-C8环烷基”、“C3-C7环烷基”、和“C3-C6环烷基”具有类似的含义。
在本发明中,术语“C3-C10环烯基”是指在环上具有3至10个碳原子的环状烯基,非限制性地包括环丙烯基、环丁烯基、环戊烯基、环己烯基、环庚烯基、环辛烯基和环癸基烯等。术语“C3-C7环烯基”具有类似的含义。
在本发明中,术语“C1-C12烷氧羰基”是指在烷基链上具有1至12个碳原子的烷氧羰基,非限制性地包括甲氧羰基、乙氧羰基、丙氧羰基、异丙氧羰基、叔丁氧羰基、苄氧羰基等。
在本发明中,术语“C1-C12烷氨基羰基”是指在烷基链上具有1至12个碳原子的烷氨基羰基,非限制性地包括甲氨基羰基、乙氨基羰基、丙氨基羰基、异丙氨基羰基、叔丁氨基羰基、苄氨基羰基、二甲氨基羰基等。
在本发明中,术语“C5-C9呋喃糖基”是指在具有5至9个碳原子的呋喃糖基,其中糖基的1位与主链相连,非限制性地包括呋喃核糖基、呋喃脱氧核糖基、呋喃半乳糖基等。
在本发明中,术语“C5-C9吡喃糖基”是指具有5至9个碳原子的吡喃糖基,其中糖基的1位与主链相连,非限制性地包括吡喃葡萄糖基、吡喃葡萄糖醛酸糖基、吡喃鼠李糖基、吡喃半乳糖基、吡喃甘露糖基、吡喃木糖基等。
在本发明中,术语“芳环”或“芳基”具有相同的含义,优选地“芳基”为“C6-C12芳基”或“C6-C10芳基”。术语“C6-C12芳基”是指在环上不含杂原子的具有6至12个碳原子的芳香族环基,如苯基、萘基等。术语“C6-C10芳基”具有类似的含义。
在本发明中,术语“芳香杂环”或“杂芳基”具有相同的含义,指包含一个到多个杂原子的杂芳族基团。这里所指的杂原子包括氧、硫和氮。例如呋喃基、噻吩基、吡啶基、吡唑基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、咪唑基、四唑基等。所述杂芳基环可以稠合于芳基、杂环基或环烷基环上,其中与母体结构连接在一起的环为杂芳基环。杂芳基可以是任选取代的或未取代的。
在本发明中,术语“3-12元杂环基”是指在环上含有1~3个选自氧、硫和氮中的杂原子的饱和或不饱和的3-12元环基,例如二氧杂环戊基等。术语“3-7元杂环基”具有类似的含义。
在本发明中,术语“取代”指特定的基团上的一个或多个氢原子被特定的取代基所取代。特定的取代基为在前文中相应描述的取代基,或各实施例中所出现的取代基。除非特别说明,某个取代的基团可以在该基团的任何可取代的位点上具有一个选自特定组的取代基,所述的取代基在各个位置上可以是相同或不同的。环状取代基,例如杂环烷基,可以与另一个环相连,例如环烷基,从而形成螺二环系,例如,两个环具有一个共用碳原子。本领域技术人员应理解,本发明所预期的取代基的组合是那些稳定的或化学上可实现的组合。所述取代基例如(但并不限于):C1-8烷基、C2-8烯基、C2-8炔基、C3-8环烷基、3-至12-元杂环基,芳基、杂芳基、卤素、羟基、羧基(-COOH)、C1-8醛基、C2-10酰基、C2-10酯基、C1-C12烷氧羰基、氨基、烷氧基、C1-10磺酰基等。
PRMT抑制剂化合物
本发明中提供了一类具有PRMT抑制活性的化合物,或其药学上可接受的盐或氘代产物:
其中,各基团的定义如上文中所述。本发明中,优选的化合物具有如实施例化合物P001-P334任一所示的结构。
药物组合物和施用方法
由于本发明化合物具有优异的I型PRMT抑制的活性,因此本发明化合物及其各种晶型,药学上可接受的无机或有机盐,水合物或溶剂合物,以及含有本发明化合物为主要活性成分的药物组合物可用于治疗、预防以及缓解由于PRMT的活性或表达量异常引起的相关疾病。
本发明的药物组合物包含安全有效量范围内的本发明化合物或其药理上可接受的盐及药理上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。通常,药物组合物含有1-2000mg本发明化合物/剂,更佳地,含有5-500mg本发明化合物/剂。较佳地,所述的“一剂”为一个胶囊或药片。
“药学上可以接受的载体”指的是:一种或多种相容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明的化合物以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明化合物或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、瘤内、直肠、肠胃外(静脉内、肌肉内或皮下)、和局部给药。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中,活性化合物与至少一种常规惰性赋形剂(或载体)混合,如柠檬酸钠或磷酸二钙,或与下述成分混合:(a)填料或增容剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(b)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶;(c)保湿剂,例如,甘油;(d)崩解剂,例如,琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠;(e)缓溶剂,例如石蜡;(f)吸收加速剂,例如,季胺化合物;(g)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(h)吸附剂,例如,高岭土;和(i)润滑剂,例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠,或其混合物。胶囊剂、片剂和丸剂中,剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备,如肠衣和其它本领域公知的材料。它们可包含不透明剂,并且,这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时,活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例知,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外,悬浮液可包含悬浮剂,例如,乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
用于局部给药的本发明化合物的剂型包括软膏剂、散剂、贴剂、喷射剂和吸入剂。活性成分在无菌条件下与生理上可接受的载体及任何防腐剂、缓冲剂,或必要时可能需要的推进剂一起混合。
本发明化合物可以单独给药,或者与其他药学上可接受的化合物联合给药。在一些优选的实施方式中,本发明的化合物可以与其他小分子化合物一同形成PROTAC,或者与其他大分子化合物例如单抗共同形成ADC施用。
使用药物组合物时,是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人),其中施用时剂量为药学上认为的有效给药剂量,对于60kg体重的人而言,日给药剂量通常为1~2000mg,优选5~500mg。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。
通用制备方法:
中间体合成1:2-(2,3-二氟-6,9-二氢-5H-苯并[7]环戊烯-7-基)-4,4,5,5-四甲 基-1,3,2-二氧杂硼烷(中间体A)的合成:
步骤1:将1,2-二溴-4,5-二氟苯(A-1)(2.0克,7.36毫摩尔,1当量.)和丙烯酸甲酯(1.90克,22.1毫摩尔,1.99毫升,3.0当量.)溶在二甲基甲酰胺(10毫升)中,加四丁基溴化铵(2.37克,7.36毫摩尔,1.0当量.),碳酸钾(2.54克,18.4毫摩尔,2.5当量.),反应液用氮气置换1分钟,加醋酸钯(33.03毫克,147微摩尔,0.02当量.)。反应液在80摄氏度搅拌16小时。反应液抽滤,滤饼用乙酸乙酯(50毫升)洗3次,有机层用水(100毫升)洗,硫酸镁干燥,抽滤,滤液减压浓缩至干。经柱层析色谱纯化(二氧化硅,15%乙酸乙酯在石油醚中)得白色固体化合物(2E,2'E)-二甲基3,3'-(4,5-二氟-1,2-亚苯基)二丙烯酸酯(A-2)(6.0克,21.26毫摩尔,96.3%产率)1H NMR(400MHz,CDCl3)δ(ppm)7.93(d,2H),7.39(t,2H),6.31(d,2H),3.85(s,6H),
步骤2:将(2E,2'E)-二甲基3,3'-(4,5-二氟-1,2-亚苯基)二丙烯酸酯(A-2)(6.0克,21.3毫摩尔,1当量.)溶在甲醇(150毫升)中,加钯/碳(1.0克,10%)反应液减压除气用氢气置换多次。反应液在氢气球氛围下反应搅拌16小时。反应液垫硅藻土抽滤,滤饼用乙酸乙酯(50毫升)冲洗3次。滤液减压浓缩至干。经柱层析色谱纯化(二氧化硅,15%乙酸乙酯在石油醚中)得无色油状化合物3,3'-(4,5-二氟-1,2-亚苯基)二丙酸二甲酯(A-3)(5.8克,20.26毫摩尔,95.31%产率)。1H NMR(400MHz,CDCl3)δ(ppm)6.98(t,2H),3.71(s,6H),2.94(t,4H),2.61(t,4H);
步骤3:在95摄氏度将3,3'-(4,5-二氟-1,2-亚苯基)二丙酸二甲酯(A-3)(1.0克,3.49毫摩尔,1当量)的二甲苯(5毫升)溶液搅拌条件下缓慢滴加到NaH(209.59毫克,5.24毫摩尔,60%纯度,1.5当量.)在二甲苯(5毫升)的悬浊液中,每加1毫升的3,3'-(4,5-二氟-1,2-亚苯基)二丙酸二甲酯(A-3)二甲苯溶液滴加一滴无水乙醇。滴加完成反应温度升至115摄氏度,在此温度继续反应1.5小时。6个反应平行设置。LC-MS检测反应完成,目标产物生成。合并6个反应用冰水(30毫升)和1M盐酸水溶液(30毫升)萃灭,用乙酸乙酯(40毫升)萃取3次。有机层硫酸镁干燥,抽滤,滤液减压浓缩至干得黄色油状粗品2,3-二氟-7-氧代-6,7,8,9-四氢-5H-苯并[7]环戊烯-6-羧酸甲酯(A-4)(5.3克粗产品)不需纯化直接用于下一步反应。LCMS:(ESI)m/z=254.7[M+1]+,268.8[M+14]+;
步骤4:将2,3-二氟-7-氧代-6,7,8,9-四氢-5H-苯并[7]环戊烯-6-羧酸甲酯(A-4)(5.3克,20.85毫摩尔,1当量.)溶在乙醇(60毫升)中,加氢氧化钠(1M水溶液,62.5毫升,3.0当量.),反应液在90摄氏度反应2小时。LC-MS检测反应完成,目标产物生成。反应液减压浓缩至干,用乙酸乙酯(30毫升)稀释,用水(30毫升)洗,有机层无水硫酸镁干燥,抽滤,滤液减压浓缩至干。经柱层析色谱纯化(二氧化硅,12%乙酸乙酯在石油醚中)得黄色固体化合物2,3-二氟-8,9-二氢-5H-苯并[7]环戊烯-7(6H)-酮(A-5)(2.6克,13.2毫摩尔,两步收率78.9%).。1H NMR(400MHz,CDCl3)δ(ppm)7.06(t,2H),2.78-2.95(m,4H),2.53-2.69(m,4H),
步骤5:将2,3-二氟-8,9-二氢-5H-苯并[7]环戊烯-7(6H)-酮(A-5)(1.0克,5.10毫摩尔,1当量.)溶在四氢呋喃(10毫升)中,零下70摄氏度加双(三甲硅基)氨基锂(1M四氢呋喃溶液,5.61毫升,1.1当量.),氮气保护下在零下70摄氏度反应1小时,零下70摄氏度加N-苯基双(三氟甲烷磺酰)亚胺(2.00克,5.61毫摩尔,1.1当量.),反应液在缓慢升至室温15小时.TLC(石油醚:乙酸乙酯=8:1,Rf=0.8)检测反应完成。反应液用水(25毫升)萃灭,用乙酸乙酯(15毫升)萃取3次。有机层硫酸镁干燥,抽滤,滤液减压浓缩至干。经柱层析色谱纯化(二氧化硅,5%乙酸乙酯在石油醚中)得无色油状化合物2,3-二氟-6,9-二氢-5H-苯并[7]环戊烯-7-基三氟甲磺酸酯(A-6)(1.27克,3.87毫摩尔,75.91%产率)。1H NMR(400MHz,CDCl3)δ(ppm)6.87-7.09(m,2H),5.89-5.97(m,1H),3.35-3.49(m,2H),2.89-3.02(m,2H),2.55-2.75(m,2H);
步骤6:将2,3-二氟-6,9-二氢-5H-苯并[7]环戊烯-7-基三氟甲磺酸酯(A-6)(1.27克,3.87毫摩尔,1当量.)和双联嚬哪醇硼酸酯(1.08克,4.26毫摩尔,1.1当量.)溶在二氧六环(20毫升)中加醋酸钾(1.14克,11.61毫摩尔,3.0当量.),1,1-双(二苯基磷)二茂铁氯化钯(283.09毫克,386.89微摩尔,0.1当量.),反应液用氮气置换1分钟.反应液在氮气保护下100摄氏度搅拌16小时。TLC(石油醚:乙酸乙酯=8:1,Rf=0.8)检测原料消耗完全,有新点生成。反应液冷却至室温,用水(20毫升)稀释,用乙酸乙酯(20毫升)萃取3次。有机层硫酸镁干燥,抽滤,滤液减压浓缩至干。经柱层析色谱纯化(二氧化硅,3%乙酸乙酯在石油醚中)得黄色固体化合物2-(2,3-二氟-6,9-二氢-5H-苯并[7]环戊烯-7-基)-4,4,5,5-四甲基-1,3,2-二氧杂硼烷(中间体A)(880毫克,2.87毫摩尔,74.3%产率)。1H NMR:(400MHz,CDCl3)δ(ppm)6.95(m,1H),6.86(m,1H),6.54-6.69(m,1H),3.45-3.58(m,2H),2.87-3.01(m,2H),2.29-2.54(m,2H),1.25(s,12H)
中间体合成2:4-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-1-(间甲苯基)- 1,2,3,6-四氢吡啶(中间体B)的合成:
步骤1:将1-苄基哌啶-4-酮(B-1)(100克,528毫摩尔,1.0当量.)溶在丙酮(700毫升)中,加碘甲烷(90.0克,634毫摩尔,39.5毫升,1.2当量.)反应液在20摄氏度搅拌16小时。白色固体析出。反应液抽滤,滤饼用干燥的丙酮(200毫升)冲洗2次,收集滤饼减压浓缩至干得类白色固体1-苄基-1-甲基-4-氧代哌啶-1-碘化物(B-2)(297克,897毫摩尔,84.86%产率)不需纯化直接用于下一步反应。.
步骤2:将1-苄基-1-甲基-4-氧代哌啶-1-碘化物(B-2)(162克,489毫摩尔,1.3当量.)在乙醇(400毫升)和水(200毫升)的浑浊液分批加到回流(90摄氏度)的3-甲基苯胺(40克,373毫摩尔,1.0当量.)和碳酸钾(7.74克,56.0毫摩尔,0.15当量.)的乙醇(500毫升)中.反应液在90摄氏度再搅拌40分钟.TLC(石油醚:乙酸乙酯=4:1,Rf=0.5)检测反应完成,新点生成。反应液用水(300毫升)稀释,用二氯甲烷(200毫升)萃取3次。有机层硫酸镁干燥,抽滤,滤液减压浓缩至干。经柱层析色谱纯化(二氧化硅,12%乙酸乙酯在石油醚中)得黄色糖浆状化合物1-(间甲苯基)哌啶-4-酮(B-3)(59克,312毫摩尔,83.5%产率);1H NMR(400MHz,CDCl3)δ(ppm)7.21(t,1H),6.79-6.89(m,2H),6.75(d,1H),3.61(t,4H),2.59(t,4H),2.35(s,3H)
步骤3:将1-(间甲苯基)哌啶-4-酮(B-3)(90克,475毫摩尔,1当量.)和1,1,2,2,3,3,4,4,4-九氟丁烷-1-磺酰氟(216克,715毫摩尔,1.5当量.)在四氢呋喃(1200毫升)中,0摄氏度滴加DBU(217克,1.43mol,215毫升,3当量.)。反应液25摄氏度搅拌3小时。LCMS检测反应完成。反应液用水(1L)稀释,用10%磷酸调pH 3~4,用甲基叔丁基醚(1L)萃取3次。有机层硫酸镁干燥,抽滤,滤液减压浓缩至干得粗品,将粗品分散到石油醚(1.5L)中20摄氏度搅拌1小时,抽滤,滤液减压浓缩至干得黄色油状物1-(间甲苯基)-1,2,3,6-四氢吡啶-4-基1,1,2,2,3,3,4,4,4,4-九氟丁烷-1-磺酸酯(B-4)(175克粗产物),不需纯化直接用于下一步反应。LCMS:(ESI)m/z=472.1[M+1]+;
步骤4:两个反应平行设置。1-(间甲苯基)-1,2,3,6-四氢吡啶-4-基1,1,2,2,3,3,4,4,4,4-九氟丁烷-1-磺酸酯(B-4)(70克,148毫摩尔,1.0当量),4,4,4',4',5,5,5',5'-八甲基-2,2'-双(1,3,2-二氧杂硼烷)(42.0克,165.毫摩尔,1.11当量.),在1,4-二氧六环(1000毫升)中,加醋酸钾(44克,448毫摩尔,3.02当量.),反应液减压除气氮气置换几次,加2-二环己基磷-2,4,6-三异丙基联苯(4.3克,9.02毫摩尔,0.06当量.)和三(二亚苄基丙酮)二钯(4.10克,4.47毫摩尔,0.03当量.)。反应液在氮气保护下90摄氏度搅拌16小时。LCMS检测反应完成。反应液冷却至室温,反应液抽滤,滤饼用石油醚(500毫升)冲洗3次,滤液减压浓缩至干.经柱层析色谱纯化(二氧化硅,5%乙酸乙酯在石油醚中)得粗品,粗品用正戊烷(150毫升)打浆得黄色固体4-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-1-(间甲苯基)-1,2,3,6-四氢吡啶(中间体B)(32克,101.60毫摩尔,34.21%产率,95%纯度)。LCMS:(ESI)m/z=300.2[M+1]+;1H NMR(400MHz,CDCl3)δ(ppm)7.10-7.22(m,1H),6.70-6.81(m,2H),6.56-6.69(m,2H),3.76-3.83(m,2H),3.33(t,2H),2.38-2.45(m,2H),2.38-2.46(m,1H),2.34(s,3H),1.30(s,12H)
步骤1:溴化氢(196.23克,800.34毫摩尔,131.70毫升,33%溴化氢醋酸溶液,2.5当量.),在25摄氏度下,缓慢滴加1小时到2,2'-(1,2-亚苯基)二乙腈(C-1)(50克,320.14毫摩尔,1当量.)的醋酸(60毫升)溶液中。反应液继续搅拌1小时。TLC检测到反应完全。悬浊反应液过滤,用异丙醚洗涤,获得固体化合物,减压干燥,得到亮黄色固体4-溴-1H-苯并[d]氮杂-2-胺(C-2)。亮黄色固体粗产物无需纯化,直接用于下一步反应。
步骤2:4-溴-1H-苯并[d]氮杂-2-胺(C-2)(88克,276.72毫摩尔,1.0当量,溴化氢盐酸盐)溶解在水(600毫升)中,加热到85摄氏度。分步加入醋酸钠(29.51克,359.74毫摩尔,1.3当量.)。反应加热到95摄氏度,并搅拌6小时。TLC检测到反应完成。冷却到室温,过滤得到固体化合物,用水洗涤固体化合物,得到粉色固体1H-苯并[d]氮杂-2,4(3H,5H)-二酮(C-3)(47克)粗产物。该粗产物无需纯化,直接用于下一步反应。
步骤3:1H-苯并[d]氮杂-2,4(3H,5H)-二酮(C-3)(47克,268.29毫摩尔,1当量)溶解在甲苯溶液(50毫升)中,在氮气氛围下,缓慢滴加硼烷二甲硫醚溶液(10M,80.49毫升,3当量.)。粉色反应液加热到110摄氏度,搅拌6小时。TLC(Rf=0.40)检测表明原料反应完全。反应液冷却到室温,甲醇(115mL)缓慢滴加到反应液,滴加完毕后,加热反应液到100摄氏度,并搅拌1小时。冷却到20摄氏度,加入4M的盐酸-二氧六环,调节反应液的pH至4~5,反应在20摄氏度下搅拌2小时。反应悬浊液过滤,得到粉色固体2,3,4,5-四氢-1H-苯并[d]氮杂(中间体C)(26克,141毫摩尔,52.7%产率,盐酸盐)。
1H NMR(400MHz,DMSO-d6)δ(ppm)9.50(br,2H),7.14-7.24(m,4H),3.10-3.20(m,8H);
步骤1:将2,3,4,5-四氢-1H-苯并[d]氮杂(中间体C)(11克游离碱,74.72毫摩尔,1当量.)溶于二氯甲烷(220毫升)中,25摄氏度氮气保护下加入三乙胺(9.07克,89.7毫摩尔,1.2当量.)。0摄氏度滴加三氟甲磺酸酐(18.8克,89.7毫摩尔,1.2当量.),反应液在0摄氏度搅拌1小时。LCMS检测反应完成。反应液依次用饱和的碳酸氢钠水溶液(200毫升)洗一次,1M的盐酸水溶液(200毫升)洗两次,饱和食盐水溶液(200毫升)洗一次。有机相用硫酸镁干燥,抽滤。滤液减压浓缩至干,经柱层析色谱纯化(二氧化硅,13%的乙酸乙酯在石油醚中)得白色固体1-(4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)-2,2,2-三氟乙酮(D-1)(16克,65.8毫摩尔,88.0%产率)。LCMS:(ESI)m/z=244.1[M+H]+;1H NMR(400MHz,CDCl3)δ(ppm)7.15-7.24(m,4H),3.77-3.83(m,2H),3.70-3.75(m,2H),2.98-3.04(m,4H);
步骤2:两个反应平行设置,0摄氏度将1-(4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)-2,2,2-三氟乙酮(D-1)(8.0克,32.9毫摩尔,1.0当量.)加到浓硫酸(32毫升)中,搅拌10分钟得到一个灰黄色溶液。0摄氏度在20分钟内分批加入硝酸钾(2.66克,26.3毫摩尔,0.8当量)。反应液在0摄氏度搅拌30分钟。TLC检测原料消耗完全。将反应液缓慢倒入搅拌的冰水(50毫升)中,用乙酸乙酯(50毫升)萃取三次。有机层用饱和食盐水(50毫升)洗涤一次,硫酸镁干燥,抽滤,滤液减压浓缩至干,经柱层析色谱纯化(二氧化硅,15%的乙酸乙酯在石油醚中)得白色固体2,2,2-三氟-1-(7-硝基-4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)乙酮(D-2)(8.6克,29.8毫摩尔,45.2%产率,99.7%纯度)。LCMS:(ESI)m/z=288.9[M+H]+;1HNMR(400MHz,CDCl3)δ(ppm)8.05-8.10(m,2H),7.32-7.39(m,1H),3.80-3.87(m,2H),3.77(m,2H),3.09-3.17(m,4H)
步骤3:将2,2,2-三氟-1-(7-硝基-4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)乙酮(D-2)(4.3克,14.9毫摩尔,1.0当量.)溶于甲醇(130毫升)中,氮气保护下加入10%的湿钯碳(794毫克,746微摩尔)。悬浊液用氢气球置换三次,反应在氢气氛围下25摄氏度搅拌16小时。LCMS检测反应完成。反应液抽滤,滤液减压浓缩至干,经柱层析色谱纯化(二氧化硅,30%的乙酸乙酯在石油醚中)得亮黄色固体1-(7-氨基-4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)-2,2,2-三氟乙酮(D-3)(6.6克,25.5毫摩尔,85.4%产率,99.7%纯度)。LCMS:(ESI)m/z=259.0[M+H]+;1H NMR(400MHz,CDCl3)δ(ppm)6.94(dd,1H),6.47-6.55(m,2H),3.71-3.78(m,2H),3.57-3.70(m,4H),2.83-2.94(m,4H)
步骤4:0摄氏度将1-(7-氨基-4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)-2,2,2-三氟乙酮(D-3)(4.5克,17.4毫摩尔,1.0当量.)溶于水(58毫升)和硫酸(9.57克,97.6毫摩尔,5.6当量.)的混合溶液中,滴加NaNO2(1.56克,22.6毫摩尔,1.0当量.)的水溶液(29毫升)。滴加完成,搅拌10分钟。NaI(3.92克,26.1毫摩尔,1.5当量.)的硫酸(1摩尔每升,5.8毫升)水溶液加入到上述溶液中。反应自然升温至25摄氏度搅拌16小时。TLC检测原料消耗完全。反应液用二氯甲烷(100毫升)萃取三次。有机层用半饱和的硫代硫酸钠水溶液(100毫升)洗两次,硫酸镁干燥,抽滤,滤液减压浓缩至干,经柱层析色谱纯化(二氧化硅,4.3%的乙酸乙酯在石油醚中)得白色固体2,2,2-三氟-1-(7-碘-4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)乙酮(D-4)(4.7克,12.7毫摩尔,73.1%产率)。1H NMR(400MHz,CDCl3)δ(ppm)7.46-7.57(m,2H),6.86-6.94(m,1H),3.72-3.83(m,2H),3.62-3.72(m,2H),2.93(m,4H);19F NMR(376MHz,CDCl3)δ(ppm)-68.07
步骤5:将2,2,2-三氟-1-(7-碘-4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)乙酮(D-4)(250毫克,677微摩尔,1.0当量.)溶于二甲基甲酰胺(2毫升)中,25摄氏度氮气氛围下,依次加入氟磺酰二氟乙酸甲酯(651毫克,3.39毫摩尔,5当量.),碘化亚铜(26毫克,135微摩尔,0.2当量.)和氮甲基吡咯烷酮(806毫克,8.13毫摩尔,12当量.)。反应加热到80摄氏度,搅拌12小时。LCMS检测反应完成。反应液用水(10毫升)稀释,抽滤。滤液用乙酸乙酯萃取(10毫升)两次。有机层用硫酸镁干燥,抽滤,减压浓缩至干,经柱层析色谱纯化(二氧化硅,4%的乙酸乙酯在石油醚中)得黄色固体2,2,2-三氟-1-(7-(三氟甲基)-4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)乙酮(D-5)(180毫克,578微摩尔,85.4%产率)。
步骤6:将2,2,2-三氟-1-(7-(三氟甲基)-4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)乙酮(D-5)(120毫克,386微摩尔,1.0当量.)溶于甲醇(3毫升)中,一次性加入碳酸钾(160毫克,1.16毫摩尔,3当量.)。反应加热至50摄氏度搅拌12小时。LCMS检测原料消耗完全,目标产物生成。反应液浓缩至干。加入水(5毫升),用乙酸乙酯(5毫升)萃取三次。有机层用硫酸镁干燥,抽滤,减压浓缩至干,得黄色糖浆状7-(三氟甲基)-2,3,4,5-四氢-1H-苯并[d]氮杂(中间体D)(80毫克,粗品),无需进一步纯化直接用于下步反应。LCMS:(ESI)m/z=215.9[M+H]+;
步骤1:将2-(2-溴乙氧基)四氢-2H-吡喃(E-1)(E-1)(18克,86.09毫摩尔,1.0当量)和4,4,4',4',5,5,5',5'-八甲基-2,2'-双(1,3,2-二氧杂硼烷)(26.2克,103毫摩尔,1.2当量)溶于二甲基甲酰胺(350毫升)中,加入甲醇锂(6.54克,172.18毫摩尔,2.0当量),碘化亚铜(1.64克,8.61毫摩尔,0.1当量)和三苯基膦树脂(2.25克,~3毫摩尔/克,8.61毫摩尔,0.1当量)。反应液在25摄氏度搅拌12小时。反应检测完全后,加入二氯甲烷(200毫升)稀释,通过加硅藻土过滤,滤饼用二氯甲烷(100毫升)洗涤2次,合并滤液,减压浓缩至干。倒入饱和氯化铵溶液中,用叔丁基甲醚(200毫升)萃取3次。所得有机相分别用水(300毫升)和饱和食盐水(300毫升)洗涤,无水硫酸钠干燥,抽滤,滤液减压浓缩至干。得无色油状4,4,5,5-四甲基-2-(2-(((四氢-2H-吡喃-2-基)氧基)乙基)-1,3,2-二氧杂硼烷(E-2)(19.0克,粗品),粗品无需进一步纯化可直接用于下一步反应。1H NMR(400MHz,CDCl3)δ(ppm)4.62(t,1H),3.83-3.94(m,2H),3.46-3.59(m,2H),1.77-1.91(m,1H),1.65-1.74(m,1H),1.45-1.61(m,4H),1.25(s,12H),1.19(t,2H)
步骤2:将4,4,5,5-四甲基-2-(2-(((四氢-2H-吡喃-2-基)氧基)乙基)-1,3,2-二氧杂硼烷(E-2)(19克,74.18毫摩尔,1当量)溶于四氢呋喃(540毫升)中,并将氟化氢钾(17.38克,222.53毫摩尔,7.33毫升,3.0当量)溶于水(60毫升),加入到上述溶液,25摄氏度搅拌2小时。反应液减压浓缩至干,冻干得白色固体。用干燥丙酮(50毫升)洗涤4次,抽滤,滤液减压浓缩至干。所得固体用叔丁基甲醚(100毫升)打浆纯化,过滤收集,干燥得白色固体(2-(((四氢-2H-吡喃-2-基)氧基)乙基)三氟硼酸钾(E-3)(13.5克,57.18毫摩尔,77.09%产率)。1H NMR(400MHz,DMSO-d6)δ(ppm)4.44(dd,1H),3.72(ddd,1H),3.58(ddd,1H),3.33-3.39(m,1H),3.23(ddd,1H),1.64-1.77(m,1H),1.50-1.60(m,1H),1.29-1.49(m,4H),0.20-0.45(m,2H)
步骤3:将1,2-二溴-4,5-二氟苯(E-4)(2.0克,7.36毫摩尔,1当量)和(2-(((四氢-2H-吡喃-2-基)氧基)乙基)三氟硼酸钾(E-3)(3.99克,16.92毫摩尔,2.30当量)溶于水(10毫升)和二氧六环(50毫升)中,分别加入双(1-金刚烷基)-丁基-膦(527.49毫克,1.47毫摩尔,0.2当量),碳酸铯(14.38克,44.14毫摩尔,6.0当量)和醋酸钯(495.45毫克,2.21毫摩尔,0.3当量),反应用氮气置换5分钟。100摄氏度搅拌16小时。TLC(石油醚:乙酸乙酯=8:1)检测原料消耗完全,有新点生成。反应液通过硅藻土过滤,然后加水(30毫升)稀释,乙酸乙酯(50毫升)萃取3次,合并有机相并用食盐水(100毫升)洗涤,无水硫酸镁干燥,抽滤,滤液减压浓缩至干。经柱层析色谱纯化(二氧化硅,10%的乙酸乙酯在石油醚中)得黄色油状2,2'-((((4,5-二氟-1,2-亚苯基)双(乙烷-2,1-二基))双(氧基))双(四氢-2H-吡喃)(E-5)(1.25克,3.37毫摩尔,45.87%产率)。
1H NMR(400MHz,CDCl3)δ(ppm)7.03(t,1H),6.97-7.09(m,1H),4.56-4.60(m,2H),3.91(td,2H),3.68-3.77(m,2H),3.57(td,2H),3.42-3.52(m,2H),2.91(t,4H),1.75-1.87(m,2H),1.65-1.74(m,2H),1.45-1.63(m,8H)
步骤4:将2,2'-((((4,5-二氟-1,2-亚苯基)双(乙烷-2,1-二基))双(氧基))双(四氢-2H-吡喃)(E-5)(1.25克,3.37毫摩尔,1当量)溶于甲醇(15毫升)中,加入一水合对甲苯磺酸(801.08毫克,4.21毫摩尔,1.2当量)。反应液在25摄氏度搅拌16小时。TLC(石油醚:乙酸乙酯=10:1)检测原料消耗完全,有新点生成。减压浓缩除去溶剂,然后加入二氯甲烷(20毫升)和饱和碳酸氢钠溶液(20毫升),水相用二氯甲烷(20毫升)萃取5次。有机层用饱和食盐水(50毫升)洗涤,无水硫酸镁干燥,抽滤,滤液减压浓缩至干。得黄色固体2,2'-(4,5-二氟-1,2-亚苯基)二乙醇(E-6)(700毫克,3.46毫摩尔,98.65%产率),粗品无需纯化可直接用于下一步反应。1H NMR(400MHz,CDCl3)δ(ppm)7.03(t,2H),3.86(t,4H),2.88(t,4H),1.97(br,2H)
步骤5:将2,2'-(4,5-二氟-1,2-亚苯基)二乙醇(E-6)(700毫克,3.46毫摩尔,1当量)和三乙胺(1.75克,17.31毫摩尔,2.41毫升,5.0当量)溶于二氯甲烷(15毫升)中,在零摄氏度加入甲磺酸酐(1.51克,8.65毫摩尔,2.5当量)。反应液在0-25摄氏度搅拌1小时。TLC(石油醚:乙酸乙酯=10:1)检测原料消耗完全,有新点生成。滴加饱和碳酸氢钠(20毫升)猝灭,二氯甲烷(20毫升)萃取3次,合并有机相,干燥,抽滤,滤液减压浓缩至干。得黄色固体(4,5-二氟-1,2-亚苯基)双(乙烷-2,1-二基)二甲磺酸酯(E-7)(1.32克)粗品,无需进一步纯化可直接用于下一步反应。1H NMR(400MHz,CDCl3)δ(ppm)7.07(t,2H),4.39(t,4H),3.08(t,4H),2.98(s,6H)
步骤6:将(4,5-二氟-1,2-亚苯基)双(乙烷-2,1-二基)二甲磺酸酯(E-7)(1.22克,3.40毫摩尔,1当量)溶于1,2-二氯乙烷(20毫升)中,加入苄胺(3.65克,34.04毫摩尔,3.71毫升,10当量),反应液在50摄氏度搅拌16小时。LCMS显示反应完全。加饱和碳酸氢钠(15毫升),用二氯甲烷(15毫升)萃取2次,合并有机相,无水硫酸镁干燥,抽滤,滤液减压浓缩至干。经柱层析色谱纯化(二氧化硅,5%的乙酸乙酯在石油醚中)得浅黄色液体N-苄基-7,8-二氟-2,3,4,5-四氢-1H-苯并[d]氮杂(E-8)(600毫克,1.98毫摩尔,58.04%产率,90%纯度)。LCMS:(ESI)m/z=273.8[M+1]+,
步骤7:将N-苄基-7,8-二氟-2,3,4,5-四氢-1H-苯并[d]氮杂(E-8)(600毫克,2.20毫摩尔,1当量.)溶于甲醇(15毫升)的盐酸/甲醇(1毫升),加入10%钯/碳(233.62毫克,219.52微摩尔,0.1当量)。反应在真空下用氢气置换数次。反应在氢气球(15Psi)下50摄氏度搅拌16小时。LCMS显示反应完全。减压浓缩除溶剂得白色固体7,8-二氟-2,3,4,5-四氢-1H-苯并[d]氮杂(中间体E)(400毫克盐酸盐粗产品),该粗产品无需进一步纯化直接用于下步反应。LCMS:(ESI)m/z=184.0[M+1]+,1H NMR(400MHz,DMSO-d6)δ(ppm)8.83(br s,1H),7.31(t,2H),2.98-3.16(m,8H)
中间体合成6:2-(6,9-二氢-5H-苯并[7]环戊烯-7-基)-4,4,5,5-四甲基-1,3,2-二氧杂硼烷(中间体F)的合成:
中间体F的合成可以参考中间体A的合成。1HNMR(400MHz,CHCl3)δ(ppm)7.15-7.18(m,2H),7.04-7.09(m,2H),6.62-6.73(m,1H),3.55-3.62(m,2H),3.01-3.07(m,2H),2.46-2.53(m,2H),1.21-1.27(m,12H)
步骤1:氮气保护下将2-氯-6-甲基烟醛(1-1)(100毫克,643微摩尔,1当量.),2,3,4,5-四氢-1H-苯并[d]氮杂(中间体C)(104毫克,707微摩尔,1.1当量.)溶于DMF(2mL),加入DIPEA(166毫克,1.29毫摩尔,2当量.),然后反应液100℃搅拌反应16小时.LCMS显示反应完全。反应液浓缩后柱层析分离纯化(硅胶柱,0-7%乙酸乙酯/石油醚梯度洗脱)得到黄色固体化合物2-(4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)-6-甲基烟醛(1-2)(90毫克,314.26微摩尔,48.89%产率,93%纯度).LCMS:(ESI)m/z=267.1[M+1]+;
步骤2:化合物2-(4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)-6-甲基烟醛(1-2)(110毫克,413微摩尔,1.0当量.)与甲基(2-(甲基氨基)乙基)氨基甲酸叔丁酯(78毫克,413微摩尔,1.0当量.)溶于10ML二氯甲烷,滴加AcOH(25毫克,413微摩尔,1当量.),黄色反应液20℃搅拌2小时。分批加入NaBH(OAc)3(263毫克,1.24毫摩尔,3当量.),黄色反应液20℃搅拌14小时,LCMS显示反应完全。滴加饱和NaHCO3(sat.20mL)水溶液淬灭反应,二氯甲烷萃取(20mL×3)。有机相饱和食盐水洗,硫酸镁干燥,过滤浓缩得到(2-((2-(4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)-6-甲基吡啶-3-基)甲基)(甲基)氨基)乙基)(甲基)氨基甲酸叔丁酯(1-3)(150毫克,crude)黄色粘液粗产物,无需纯化,直接用于下步反应。LCMS:(ESI)m/z=439.3[M+1]+;
步骤3:向2-((2-(4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)-6-甲基吡啶-3-基)甲基)(甲基)氨基)乙基)(甲基)氨基甲酸叔丁酯(1-3)(150毫克,342微摩尔,1.0当量)小心加入HCl/1,4-二氧六环(5mL)溶液;室温搅拌反应16小时,LCMS监测反应完全,反应液浓缩得粗产物,经制备HPLC纯化(柱:Boston Green ODS 150×30mm×5um;流动相:[water(0.05%HCl)-ACN];B%:0%-38%,9min)并收集低温冻干得黄色固体产物N1-((2-(4,5-二氢-1H-苯并[d]氮杂-3(2H)-基)-6-甲基吡啶-3-基)甲基)-N1,N2-二甲基乙烷-1,2-二胺(P110,实施例1)(110毫克,318微摩尔,93.1%产率,98%纯度)。LCMS:(ESI)m/z=339.3[M+1]+;1HNMR(400MHz,D2O)δ(ppm)8.29(d,1H),7.32(d,1H),7.27(s,4H),4.35(s,2H),3.53(t,4H),3.39(s,4H),3.16(t,,4H),2.72(s,3H),2.60(s,3H),2.46(s,3H)
实施例2:化合物N1,N2-二甲基-N1-((6-甲基-2-(1-(间甲苯基)哌啶-4-基)吡啶-
3-基)甲基)乙烷-1,2-二胺(P081)的合成
步骤1:化合物2-氯-6-甲基烟醛(2-1)(10.0克,64.3毫摩尔,1.0当量.),甲基(2-(甲基氨基)乙基)氨基甲酸叔丁酯(13.3克,70.7毫摩尔,1.1当量.)和AcOH(4.25克,70.7毫摩尔,1.1当量.)溶于二氯甲烷(150mL),并在25℃搅拌反应2小时。小心分批加入NaBH(OAc)3(40.9克,1923毫摩尔,3.0当量.),并继续室温搅拌16小时。LCMS显示原料消失,小心加入NaHCO3(300mL)淬灭反应,二氯甲烷萃取(200mL×3)。合并有机相用无水硫酸镁干燥,过滤,浓缩后柱层析分离纯化(硅胶柱,0~10%乙酸乙酯/石油醚梯度洗脱)后浓缩得黄色粘稠产物(2-((2-氯-6-甲基吡啶-3-基)甲基)(甲基)氨基)乙基)(甲基)氨基甲酸叔丁酯(2-2)(13.0克,38.4毫摩尔,59.8%产率)。LCMS:(ESI)m/z=328.0[M+H]+;1H NMR(400MHz,CDCl3)δ(ppm)7.65-7.78(m,1H),7.09(d,1H),3.60(s,2H),3.25-3.50(m,2H),2.86(s,3H),2.52-2.65(m,2H),2.52(s,3H),2.30(s,3H),1.35-1.49(m,9H)
步骤2:70mL四氢呋喃中依次加入(2-((2-氯-6-甲基吡啶-3-基)甲基)(甲基)氨基)乙基)(甲基)氨基甲酸叔丁酯(2-2)(7.02克,21.4毫摩尔,1.0当量.),4-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-1-(间甲苯基)-1,2,3,6-四氢吡啶(中间体B)(7.05克,23.6毫摩尔,1.1当量.),和磷酸三钾(9.10克,42.9毫摩尔,2.0当量.)水溶液(14mL)。反应体系经多次减压和氮气置换后加入XPhos-Pd-G2(510毫克,648微摩尔,0.03当量.),反应在氮气保护下油浴加热85℃反应30小时,LCMS监测原料消失。冷却到室温后反应液用饱和食盐水(50mL)与乙酸乙酯(100mL)稀释。分离有机相,水相用乙酸乙酯萃取,合并有机相用无水硫酸镁干燥,过滤,浓缩后柱层析分离(硅胶柱,0~10~30%乙酸乙酯/二氯甲烷梯度洗脱),浓缩得黄色粘液甲基(2-(甲基((6-甲基-1'-(间甲苯基)-1',2',3',6'-四氢-[2,4'-联吡啶]-3-基)甲基)氨基)乙基)氨基甲酸叔丁酯(2-3)(10.9克,19.9毫摩尔,93.1%产率,85%纯度,核磁检测约含15%w/w片呐醇)。LCMS:(ESI)m/z=465.2[M+1]+;1H NMR(400MHz,CDCl3)δ(ppm)7.70(d,1H),7.18(t,1H),6.99-7.08(m,1H),6.81(s,1H),6.78-6.81(m,1H),6.66(d,1H),5.84-5.93(m,1H),3.86-3.93(m,2H),3.56(t,2H),3.51(s,2H),3.21-3.41(m,2H),2.82(s,3H),2.62-2.71(m,2H),2.54(s,3H),2.39-2.52(m,2H),2.35(s,3H),2.20(s,3H),1.34-1.54(m,9H)
步骤3:将甲基(2-(甲基((6-甲基-1'-(间甲苯基)-1',2',3',6'-四氢-[2,4'-联吡啶]-3-基)甲基)氨基)乙基)氨基甲酸叔丁酯(2-3)(7.84克,16.9毫摩尔,1当量.)溶于250ML乙酸乙酯,氮气保护下加入10%潮湿Pd(OH)2/C(3.16克)。体系用氢气球多次置换后再氢气保护下室温搅拌反应36小时。LCMS监测反应完全。反应液硅藻土过滤,乙酸乙酯洗涤后合并有机相浓缩,柱层析分离纯化(硅胶柱,0~25%乙酸乙酯/二氯甲烷梯度洗脱)得黄色粘液甲基(2-(甲基((6-甲基-2-(1-(间甲苯基)哌啶-4-基)吡啶-3-基)甲基)氨基)乙基)氨基甲酸叔丁酯(2-4)(8.86克,18.0毫摩尔,76.9%产率)。LCMS:(ESI)m/z=467.4[M+1]+;1H NMR(400MHz,CDCl3)δ(ppm)7.45(d,1H),7.17(t,1H),6.92(d,1H),6.82(s,1H),6.78-6.81(m,1H),6.67(d,1H),3.76-3.86(m,2H),3.50(s,2H),3.23-3.43(m,2H),3.03-3.17(m,1H),2.84(s,3H),2.73-2.83(m,2H),2.49-2.63(m,1H),2.49(s,3H),2.33(s,3H),2.14-2.29(m,5H),1.75-1.84(m,2H),1.33-1.51(m,9H)
步骤4:将甲基(2-(甲基((6-甲基-2-(1-(间甲苯基)哌啶-4-基)吡啶-3-基)甲基)氨基)乙基)氨基甲酸叔丁酯(2-4)(11.7克,25.1毫摩尔,1.0当量.)溶于甲醇(70mL),搅拌下滴加HCl/1,4-dioxane(4M,75mL)。反应在氮气保护下室温搅拌16小时,LCMS监测反应完全。将反应液浓缩后加入约200ML甲醇并减压旋干,重复2次带除盐酸。浓缩物甲醇稀释后用活性炭加热脱色,冷却室温过滤并用甲醇洗涤,浓缩到100ML左右加入异丙醇置换甲醇,浓缩至250ML。反应乳液85℃加热30分钟,30℃搅拌10小时,冷却至室温。过滤,固体依次用异丙醇(100mL)正戊烷(200mL×2)洗涤后收集并真空干燥。固体产物溶于150ML水中,过滤,滤液冻干得白色固体产物N1,N2-二甲基-N1-((6-甲基-2-(1-(间甲苯基)哌啶-4-基)吡啶-3-基)甲基)乙烷-1,2-二胺(P081,实施例2)(盐酸盐,9.8克,19.1毫摩尔,76.2%产率,99.9%纯度)。LCMS:(ESI)m/z=367.3[M+1]+;1H NMR(400MHz,D2O)δ(ppm)8.52(d,1H),7.83(d,1H),7.52(s,1H),7.43-7.51(m,2H),7.36-7.42(m,1H),4.72(s,2H),3.93-4.07(m,3H),3.82-3.91(m,2H),3.67-3.76(m,2H),3.55-3.63(m,2H),2.85(s,3H),2.81(s,3H),2.80(s,3H),2.46-2.60(m,2H),2.39(s,3H),2.31-2.39(m,2H)
实施例3:N1-((6-氨基-2-(1-(m-甲苯基)哌啶-4-基)吡啶-3-基)甲基)-N1,N2-二
甲基乙烷-1,2-二胺(P226)的合成
步骤1:向2,6-二氯烟醛(3-1)(25克,142毫摩尔,1当量.)与双(4-甲氧基苄基)胺(40.2克,156毫摩尔,1.1当量.)的DMF(200mL)溶液加入三乙胺(17.2克,170毫摩尔,23.7mL)。反应液50℃搅拌16小时,LCMS监测反应完全。混合物倒入200ML冰水中,乙酸乙酯萃取(400mL×1,200mL×2)。合并有机相用饱和食盐水洗涤,无水硫酸镁干燥,过滤,浓缩并柱层析分离纯化(硅胶柱,0~20%乙酸乙酯/(石油醚:二氯甲烷=5:1)梯度洗脱)得白色固体化合物6-(双(4-甲氧基苄基)氨基)-2-氯烟醛(3-2)(50克,124.83毫摩尔,87.88%产率,99.08%纯度)。LCMS:(ESI)m/z=397.1[M+H]+;1HNMR(400MHz,DMSO-d6),δ(ppm)10.02(s,1H),7.86(d,1H),7.27-7.12(m,4H),6.90(d,4H),6.73(d,1H),4.78(br,4H),3.73(s,6H)
步骤2:反应瓶中依次加入6-(双(4-甲氧基苄基)氨基)-2-氯烟醛(3-2)(800毫克,2.02毫摩尔,1.0当量.),1-(间甲苯基)-4-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-3,6-二氢-2H-吡啶(中间体B)(1.02克,2.40毫摩尔,70%纯度,1.19当量),THF(6mL)和磷酸钾水溶液(856毫克磷酸钾溶于1ML水中),反应体系减压-氮气置换多次后在氮气保护下加入XPhos-Pd-G3(37毫克,43.71微摩尔,0.02当量.),氮气保护下油浴加热70℃搅拌反应2.5小时,LCMS监测产物生成。冷却到室温后反应液中加入饱和食盐水并用乙酸乙酯萃取3次。有机相合并用无水硫酸镁干燥,过滤,浓缩后柱层析分离纯化(硅胶柱,0~10~15%乙酸乙酯/石油醚梯度洗脱)得黄色粘液产物6-(双(4-甲氧基苄基)氨基)-1'-(间甲苯基)-1',2',3',6'-四氢-[2,4'-联吡啶]-3-甲醛(3-3)(1.01克,1.50毫摩尔,74.2%产率,79%纯度)LCMS:(ESI)m/z=534.3[M+1]+;
步骤3:反应瓶中加入6-(双(4-甲氧基苄基)氨基)-1'-(间甲苯基)-1',2',3',6'-四氢-[2,4'-联吡啶]-3-甲醛(3-3)(801毫克,1.50毫摩尔,1当量.)与乙酸乙酯(50mL),氮气保护下加入Pd(OH)2/C(450毫克,10%Pd(OH)2on charcoal,wet)。反应体系用氢气置换后再氢气气氛(氢气球)下室温搅拌反应18小时。反应液过滤浓缩后柱层析分离纯化(硅胶柱,0~25%乙酸乙酯/石油醚梯度洗脱)得黄色粘液产物(6-(双(4-甲氧基苄基)氨基)-2-(1-(间甲苯基)哌啶-4-基)吡啶-3-基)甲醇(3-4)(695毫克,1.23毫摩尔,64.9%产率,95%纯度)。LCMS:(ESI)m/z=538.3[M+1]+;1H NMR(400MHz,CDCl3)δ(ppm)7.34(d,1H),7.09-7.24(m,5H),6.77-6.92(m,6H),6.68(br d,1H),6.29(d,1H),4.73(s,4H),4.65(d,2H),3.81(s,6H),3.72-3.81(m,1H),2.99-3.13(m,1H),2.75-2.88(m,2H),2.33(s,3H),2.15-2.30(m,2H),1.80-1.92(m,2H),1.40(t,J=5.27Hz,1H).
步骤4:化合物(6-(双(4-甲氧基苄基)氨基)-2-(1-(间甲苯基)哌啶-4-基)吡啶-3-基)甲醇(3-4)(440毫克,818微摩尔,1当量.)加入10ML二氯甲烷中,冰浴冷却下加入Dess-Martin periodinane(347毫克,818微摩尔,1当量.),反应液室温搅拌16小时。加入20mL 10%硫代硫酸钠水溶液淬灭反应。搅拌半小时后加入50mL饱和碳酸氢钠水溶液,用二氯甲烷萃取3次。合并有机相用依次用饱和食盐水、饱和碳酸氢钠水溶液洗涤后用无水硫酸镁干燥,过滤、浓缩后柱层析分离纯化(硅胶柱0~16.8%乙酸乙酯/石油醚梯度洗脱)得黄色粘稠液体产物6-(双(4-甲氧基苄基)氨基)-2-(1-(间甲苯基)哌啶-4-基)烟醛(3-5)(250毫克,373微摩尔,45.6%产率)。LCMS:(ESI)m/z=536.2[M+1]+;
步骤5:反应瓶中加入5ML二氯甲烷,然后依次加入6-(双(4-甲氧基苄基)氨基)-2-(1-(间甲苯基)哌啶-4-基)烟醛(3-5)(250毫克,466.70微摩尔,1.0当量.)与甲基(2-(甲基氨基)乙基)氨基甲酸叔丁酯(88毫克,466微摩尔,1.0当量.),然后加入AcOH(28.03毫克,466.70微摩尔,1.0当量.)并室温搅拌2小时。分批加入NaBH(OAc)3(297毫克,1.40毫摩尔,3.0当量.)然后继续搅拌14小时。小心滴加20ML饱和碳酸氢钠水溶液淬灭反应,搅拌后用二氯甲烷萃取3次,合并有机相用饱和食盐水洗涤后用无水硫酸镁干燥。过滤、浓缩后柱层析分离纯化(硅胶柱,0~17%四氢呋喃/石油醚梯度洗脱)得黄色粘稠液体化合物(2-((6-(双(4-甲氧基苄基)氨基)-2-(1-(间甲苯基)哌啶-4-基)吡啶-3-基)间乙基)(甲基)氨基)乙基)(甲基)氨基甲酸叔丁酯(3-6)(60毫克,83.1微摩尔,17.80%产率,98%纯度)。LCMS:(ESI)m/z=708.4[M+1]+;1H NMR(400MHz,CDCl3)δ(ppm)7.24(d,J=8.28Hz,1H),7.10-7.19(m,5H),6.74-6.88(m,6H),6.65(d,J=7.28Hz,1H),6.25(d,J=8.28Hz,1H),4.69(s,4H),3.79(s,6H),3.70-3.79(m,2H),3.41(s,2H),3.21-3.41(m,2H),2.98-3.09(m,1H),2.84(s,3H),2.72-2.84(m,2H),2.44-2.59(m,2H),2.31(s,3H),2.09-2.27(m,5H),1.78-1.87(m,2H),1.36-1.49(m,9H)
步骤6:化合物(2-((6-(双(4-甲氧基苄基)氨基)-2-(1-(间甲苯基)哌啶-4-基)吡啶-3-基)间乙基)(甲基)氨基)乙基)(甲基)氨基甲酸叔丁酯(3-6)(60毫克,84.7微摩尔,1当量.)加入1ML三氟乙酸,然后加入三氟甲磺酸(29毫克,194微摩尔,2.29当量.).反应在氮气保护下室温搅拌16小时,LCMS显示反应完全。反应混合物浓缩后用制备HPLC分离纯化(柱子:Boston Green ODS 150×30mm×5um;流动相:[water(0.05%HCl)-ACN];B%:0%-25%,9min)。目标产物经冻干得黄色固体产物N1-((6-氨基-2-(1-(m-甲苯基)哌啶-4-基)吡啶-3-基)甲基)-N1,N2-二甲基乙烷-1,2-二胺(P226,实施例3)(22毫克,58.7微摩尔,69.2%产率)。LCMS:(ESI)m/z=368.3[M+1]+;1H NMR(400MHz,D2O)δ(ppm)7.91(d,J=9.29Hz,1H),7.43-7.51(m,2H),7.36-7.43(m,2H),6.98(d,1H),4.40(s,2H),3.78-3.89(m,4H),3.63-3.72(m,1H),3.49-3.62(m,4H),2.78(s,6H),2.39(s,3H),2.31-2.44(m,2H),2.18-2.30(m,2H)
实施例4:N1,N2-二甲基-N1-((4-(1-(间甲苯基)哌啶-4-基)-1H-吲唑-5-基)甲基) 乙烷-1,2-二胺(P190)的合成:
步骤1:将2-溴-4-氟苯甲酸(4-1)(23克,105毫摩尔,1.0当量.)溶于叔丁醇(200毫升)中,室温条件下加入4-二甲氨基吡啶(12.8克,105毫摩尔,1.0当量.)和二碳酸二叔丁酯(68.8克,315毫摩尔,3.0当量.)(放气),反应液氮气保护下90摄氏度反应2小时.TLC检测原料消耗完全,有一个新点生成。反应液用水(100毫升)稀释,用乙酸乙酯(150毫升)萃取两次。有机层用饱和食盐水(80毫升)洗一次,硫酸镁干燥,抽滤,滤液减压浓缩至,经柱层析色谱纯化(二氧化硅,石油醚:乙酸乙酯=10:1)得无色液体2-溴-4-氟苯甲酸叔丁酯(4-2)(26.8克,95.0毫摩尔,90.4%产率,97.5%纯度)1H NMR(400MHz,CDCl3)δ(ppm)7.77(dd,1H),7.37(dd,1H),7.02-7.10(m,1H),1.61(s,9H)
步骤2:合成二异丙基氨基锂:将二异丙基胺(5.15克,50.9毫摩尔,7.19毫升,1.4当量.)溶于四氢呋喃(100毫升)中,-70摄氏度滴加正丁基锂(2.5M,17.45毫升,1.2当量.)。滴加完成,反应液升到室温搅拌半小时得黄色的二异丙基氨基锂溶液。将2-溴-4-氟苯甲酸叔丁酯(4-2)(10克,36.35毫摩尔,1当量)溶在四氢呋喃(20毫升)中,-75摄氏度滴加到新鲜制备的二异丙基氨基锂中,反应液在-75摄氏度反应1.5小时。-75摄氏度将二甲基甲酰胺(10.6克,145毫摩尔,4.0当量.)加到反应液中继续反应0.5小时。TLC检测原料消耗完全,有新点生成。-70摄氏度滴加醋酸(20毫升)萃灭,用水(150毫升)稀释,用乙酸乙酯(200毫升)萃取两次。有机层用饱和食盐水(100毫升)洗涤,硫酸镁干燥,抽滤,滤液减压浓缩至,经柱层析色谱纯化(二氧化硅,3%的乙酸乙酯在石油醚中)得类白色固体2-溴-4-氟-3-甲酰基苯甲酸叔丁酯(4-3)(8.7克,27.7毫摩尔,76.2%产率)。1H NMR(400MHz,CDCl3)δ(ppm)10.39(s,1H),7.80(dd,1H),7.19(t,1H),1.63(s,9H)
步骤3:将2-溴-4-氟-3-甲酰基苯甲酸叔丁酯(4-3)(8.7克,28.7毫摩尔,1.0当量)溶在乙二醇二甲醚(100毫升)中,加水合肼(31.6克,537毫摩尔,85%,18.7当量.)。反应液90摄氏度搅拌1小时.LCMS检测原料消耗完全,目标产物生成。反应液冷却后用水(100毫升)稀释,乙酸乙酯(150毫升)萃取2次.有机层用饱和食盐水(100毫升)洗涤,硫酸镁干燥,抽滤,滤液减压浓缩至,经柱层析色谱纯化(二氧化硅,3%的乙酸乙酯在石油醚中)得黄色固体4-溴-1H-吲唑-5-羧酸叔丁酯(4-4)(4.5克,15.1毫摩尔,52.7%产率)。LCMS:(ESI)m/z=296.9/298.9[M+1]+;
步骤4:将4-溴-1H-吲唑-5-羧酸叔丁酯(4-4)(4.5克,15.14毫摩尔,1当量)和3.4二氢-2H-吡喃(3.82克,45.43毫摩尔,4.15毫升,3当量)溶在二氯甲烷(60毫升)中,加一水合对甲苯磺酸(288毫克,1.51毫摩尔,0.1当量).反应液在15摄氏度搅拌1小时.LC-MS检测原料消耗完全,目标产物生成。反应液用水(50毫升)稀释,用乙酸乙酯(100毫升)萃取2次.有机层用饱和食盐水(80毫升)洗涤,硫酸镁干燥,抽滤,滤液减压浓缩至,经柱层析色谱纯化(二氧化硅,3%的乙酸乙酯在石油醚中)得黄色糖浆状4-溴-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-羧酸叔丁酯(4-5)(4.5克,11.6毫摩尔,76.7%产率)LCMS:(ESI)m/z=240.9/242.9[M+1-THP-tBu]+;1H NMR(400MHz,CDCl3)δ(ppm)8.16(s,1H),7.81(d,1H),7.55(d,1H),5.72(dd,1H),3.93-4.03(m,1H),3.67-3.80(m,1H),2.43-2.59(m,1H),2.12-2.21(m,1H),2.02-2.12(m,1H),1.66-1.85(m,3H),1.64(s,9H)
步骤5:将4-溴-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-羧酸叔丁酯(4-5)(1.0克,2.62毫摩尔,1.0当量.)和4-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-1-(间甲苯基)-1,2,3,6-四氢吡啶(中间体B)(863毫克,2.89毫摩尔,1.1当量.)溶在四氢呋喃(8毫升)中,加磷酸钾(1.67克,7.87毫摩尔,3当量.)水溶液(2毫升).反应液减压除气用氮气置换几次。加(2-二环己基膦-2,4,6-三异丙基-1,1-联苯)[2-(2-氨基-1,1-联苯)]钯(II)甲磺酸酯(XPhos-Pd-克3)(67毫克,78.7微摩尔,0.03当量.)。反应液在氮气保护下80摄氏度搅拌16小时.LC-MS检测原料消耗完全,目标产物生成。反应液用水(30毫升)稀释,用乙酸乙酯(20毫升)萃取3次.有机层用饱和食盐水(20毫升)洗涤,硫酸镁干燥,抽滤,滤液减压浓缩至干,经柱层析色谱纯化(二氧化硅,3%的乙酸乙酯在石油醚中)得黄色糖浆状1-(四氢-2H-吡喃-2-基)-4-(1-(间甲苯基)-1,2,3,6-四氢吡啶-4-基)-1H-吲唑-5-羧酸叔丁酯(4-6)(800毫克,1.55毫摩尔,59.0%产率)。LCMS:(ESI)m/z=474.4[M+H]+;
步骤6:将1-(四氢-2H-吡喃-2-基)-4-(1-(间甲苯基)-1,2,3,6-四氢吡啶-4-基)-1H-吲唑-5-羧酸叔丁酯(4-6)(800毫克,1.69毫摩尔,1当量.)溶在甲醇(160毫升)中,加10%Pd/C(150毫克).反应液减压除气用氢气置换几。反应液氢气球气氛下50摄氏度搅拌32小时。LCMS检测目标产物生成。反应液抽滤,滤液减压浓缩至干,经柱层析色谱纯化(二氧化硅,30%的乙酸乙酯在石油醚中)得黄色糖浆状1-(四氢-2H-吡喃-2-基)-4-(1-(间甲苯基)哌啶-4-基)-1H-吲唑-5-羧酸叔丁酯(4-7)(630毫克,1.24毫摩尔,73.2%产率).LCMS:(ESI)m/z=476.3[M+H]+;RT=0.857min
1H NMR(400MHz,CDCl3)δ(ppm)8.31(s,1H),7.64(d,1H),7.45(d,1H),7.19(t,1H),6.80-6.91(m,2H),6.71(d1H),5.71(dd,1H),3.99-4.07(m,1H),3.86-3.94(m,2H),3.65-3.79(m,2H),2.82-3.93(m,2H),2.51-2.65(m,1H),2.37-2.49(m,2H),2.35(s,3H),2.11-2.22(m,1H),2.04-2.10(m,1H),1.93-2.02(m,2H),1.71-1.85(m,2H),1.64-1.71(m,1H),1.63(s,9H)
步骤7:将1-(四氢-2H-吡喃-2-基)-4-(1-(间甲苯基)哌啶-4-基)-1H-吲唑-5-羧酸叔丁酯(4-7)(630毫克,1.32毫摩尔,1.0当量.)溶在四氢呋喃(6毫升)中,-5摄氏度滴加四氢铝锂(1M in THF,5.5毫升,4.15当量.)。反应液在20摄氏度搅拌3小时.TLC(石油醚/乙酸乙酯=1:1)检测原料消耗完全,新点生成。反应液-5摄氏度滴加水(10毫升)萃灭,用水(5毫升)稀释,用乙酸乙酯(30毫升)萃取2次.有机层用饱和食盐水(20毫升)洗涤,硫酸镁干燥,抽滤,滤液减压浓缩至干,经柱层析色谱纯化(二氧化硅,50%的乙酸乙酯在石油醚中)得白色固体(1-(四氢-2H-吡喃-2-基)-4-(1-(间甲苯基)哌啶-4-基)-1H-吲唑-5-基)甲醇(4-8)(500毫克,849微摩尔,64.1%产率)LCMS:(ESI)m/z=406.3[M+H]+;
步骤8:将(1-(四氢-2H-吡喃-2-基)-4-(1-(间甲苯基)哌啶-4-基)-1H-吲唑-5-基)甲醇(4-8)(200毫克,493.18微摩尔,1当量.)溶在二氯甲烷(10毫升)中,加戴斯-马汀试剂(220毫克,518微摩尔,1.05当量.).反应液在25摄氏度反应6小时.LC-MS检测原料消耗完全,目标产物生成。反应液用10%硫代硫酸钠溶液(20毫升)萃灭,室温搅拌0.5小时,反应液加饱和碳酸氢钠(50毫升),用二氯甲烷(50毫升)萃取3次.有机层用饱和食盐水(50毫升)洗涤,硫酸镁干燥,抽滤,滤液减压浓缩至干,经柱层析色谱纯化(二氧化硅,30%的乙酸乙酯在石油醚中)得黄色糖浆状1-(四氢-2H-吡喃-2-基)-4-(1-(间甲苯基)哌啶-4-基)-1H-吲唑-5-甲醛(4-9)(140毫克,293微摩尔,59.4%产率)。LCMS:(ESI)m/z=404.3[M+H]+;
步骤9:将1-(四氢-2H-吡喃-2-基)-4-(1-(间甲苯基)哌啶-4-基)-1H-吲唑-5-甲醛(4-9)(200毫克,496微摩尔,1.0当量.)和甲基(2-(甲基氨基)乙基)氨基甲酸叔丁酯(112毫克,595微摩尔,1.2当量.)溶在二氯甲烷(5毫升)中,加醋酸(36毫克,595微摩尔,1.2当量.)。反应液在20摄氏度搅拌2小时。加三乙酰氧基硼氢化钠(315毫克,1.49毫摩尔,3当量.).反应液在20摄氏度搅拌14小时。LC-MS检测原料消耗完全,目标产物生成。反应液用饱和碳酸氢钠溶液(10毫升)萃灭,用水(5毫升)稀释,用二氯甲烷(20毫升)萃取2次,硫酸镁干燥,抽滤,滤液减压浓缩至干,经柱层析色谱纯化(二氧化硅,50%的乙酸乙酯在二氯甲烷中)得黄色糖浆状甲基(2-(甲基((1-(四氢-2H-吡喃-2-基)-4-(1-(间甲苯基)哌啶-4-基)-1H-吲唑-5-基)甲基)氨基)乙基)氨基甲酸叔丁酯(4-10)(210毫克,365微摩尔,73.6%产率)LCMS:(ESI)m/z=576.5[M+H]+;
步骤10:将甲基(2-(甲基((1-(四氢-2H-吡喃-2-基)-4-(1-(间甲苯基)哌啶-4-基)-1H-吲唑-5-基)甲基)氨基)乙基)氨基甲酸叔丁酯(4-10)(210毫克,365微摩尔,1.0当量.)溶在甲醇(2毫升)中加氯化氢/1,4-二氧六环(4M,2.10毫升).反应液在25摄氏度搅拌16小时。LC-MS检测原料消耗完全,目标产物生成。反应液减压浓缩至干,经制备液相色谱纯化(Boston Green ODS柱,5um二氧化硅,30mm直径,150mm长度;使用水(含有0.05%盐酸)和乙腈的极性递减的混合物作为洗脱液)得白色固体N1,N2-二甲基-N1-(((4-(1-(间甲苯基)哌啶-4-基)-1H-吲唑-5-基)甲基)乙烷-1,2-二胺(P190,实施例4)(盐酸盐,105毫克,245微摩尔,67.3%产率)。
LCMS:(ESI)m/z=392.2[M+H]+;1H NMR(400MHz,D2O)δ(ppm)8.63(s,1H),7.61(d,1H),7.54(s,1H),7.42-7.51(m,3H),7.36(d,1H),4.74(s,2H),3.86-4.02(m,2H),3.65-3.84(m,5H),3.52-3.64(m,2H),2.87(s,3H),2.70-2.94(m,2H),2.78(s,3H),2.37(s,3H),2.09-2.19(m,2H)
实施例5:N1-((4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-甲基-
1H-吲唑-5-基)甲基)-N1,N2-二甲基乙烷-1,2-二胺(P146)的合成:
步骤1:将4-溴-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-羧酸叔丁酯(4-5)(1.95克,5.11毫摩尔,1.0当量),(2,3-二氟-6,9-二氢-5H-苯并[7]环戊-7-基)-4,4,5,5-四甲基-1,3,2-二氧杂硼烷(中间体A)(1.80克,5.88毫摩尔,1.15当量),甲苯(45毫升)和磷酸钾(2.18克,10.3毫摩尔,2.01当量)溶解在水(6.5毫升)中,加入到反应瓶中,用氮气置换几次后,加入氯(2-二环己基膦基-2,4,6-三异丙基-1,1-联苯基)[2-(2-氨基-1,1-联苯)]钯(II)(0.03当量)。反应液用氮气保护,并在60摄氏度下,搅拌24小时。LCMS检测到目标产物生成。反应液冷却到25摄氏度,用水(50毫升)和乙酸乙酯(50毫升)溶解,分离有机相,然后在乙酸乙酯(50毫升)萃取3次。合并有机相,硫酸镁干燥,抽滤,滤液减压浓缩至干。经柱层析色谱纯化(二氧化硅,15%的乙酸乙酯在石油醚中,得到黄色油状物4-(2,3-二氟-6,9-二氢-5H-苯并[7]环戊烯-7-基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-羧酸叔丁酯(5-1)。LCMS:(ESI)m/z=481.2[M+1]+;
步骤2:4-(2,3-二氟-6,9-二氢-5H-苯并[7]环戊烯-7-基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-羧酸叔丁酯(5-1)(1.0当量)溶解在乙酸乙酯(50毫升),在氮气氛围下,加入氢氧化钯/碳(520毫克,10%)。反应液用氢气置换几次,并在30摄氏度,搅拌12h。LCMS检测到原料被消耗,目标产物生成。过滤反应液,得到白色固体4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-羧酸叔丁酯(5-2),无需进一步纯化直接用于下一步反应。LCMS:(ESI)m/z=399.3[M+1-THP]+;1H NMR(400MHz,CDCl3)δ(ppm)7.98(s,1H),7.64(d,1H),7.43(d,1H),6.94-7.05(m,2H),5.70(dd,1H),3.98-4.07(m,1H),3.89-3.98(m,1H),3.69-3.80(m,1H),2.91-3.06(m,2H),2.76-2.91(m,2H),2.46-2.59(m,1H),2.11-2.23(m,3H),1.95-2.10(m,3H),1.66-1.84(m,4H),1.65(s,9H)
步骤3:4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-羧酸叔丁酯(5-2)(1.9克,3.94毫摩尔,1.0当量.)溶解在甲醇(30毫升)和四氢呋喃(30毫升),加入一水合对甲苯磺酸(297毫克,1.56毫摩尔,0.40当量.)。反应液在30摄氏度下,搅拌3.5天。LCMS检测到目标产物生成,原料剩余。反应液用饱和的碳酸氢钠溶液(20毫升)淬灭,减压浓缩除去甲醇。加入乙酸乙酯(100毫升)和水(50毫升),分离有机相,并用乙酸乙酯(50毫升)萃取2次。合并有机相,并用无水硫酸镁干燥,过滤,滤液减压浓缩至干。经薄层色谱纯化(二氧化硅,35%的乙酸乙酯在石油醚中)。减压浓缩至干,得白色固体4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-1H-吲唑-5-羧酸叔丁酯(5-3)(827毫克,2.08毫摩尔,52.7%产率)。LCMS:(ESI)m/z=399.2[M+1]+;1H NMR(400MHz,CDCl3)δ(ppm)8.06(s,1H),7.65(d,1H),7.34(d,1H),7.00(t,2H),3.90-4.02(m,1H),2.92-3.06(m,2H),2.76-2.90(m,2H),2.14-2.27(m,2H),1.98-2.11(m,2H),1.64(s,9H)
步骤4:4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-1H-吲唑-5-羧酸叔丁酯(5-3)(424毫克,1.06毫摩尔,1.0当量.)溶解在二甲基甲酰胺(10毫升,先加入碳酸钾(458毫克,3.31毫摩尔,3.11当量.),加入碘单质(459毫克,1.81毫摩尔,1.7当量.)。反应液在15~20摄氏度下,搅拌16小时。LCMS检测到69%的目标产物,30%的原料剩余。另外的碘单质(135毫克,532微摩尔,0.5当量.)和碳酸钾180毫克,1.30毫摩尔,1.22当量.)继续加入到反应液中,并继续在15~30摄氏度搅拌3小时。LCMS检测到10%的原料剩余,目标产物形成。与之前的50毫克的粗品合并处理。反应液中加入乙酸乙酯(50毫升)和10%的硫代硫酸钠溶液(50毫升),分离有机相,水相用乙酸乙酯(50毫升)萃取3遍。合并有机相,并用10%的硫代硫酸钠溶液洗涤一次,10%氯化锂(25毫升)洗涤3次,和饱和食盐水(50毫升)洗涤一次,干燥,过滤,减压浓缩得到淡黄色泡沫状固体粗产物4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-碘-1H-吲唑-5-羧酸叔丁酯(5-4),不需进一步纯化,直接用于下一步反应。LCMS:(ESI)m/z=525.0[M+1]+;
步骤5:4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-碘-1H-吲唑-5-羧酸叔丁酯(5-4)(589毫克,1.12毫摩尔,1.0当量.)和3,4-二氢吡喃(420毫克,4.99毫摩尔,4.44当量.)溶解在二氯甲烷(15毫升)中,在冰浴0~5摄氏度温度下,加入对甲苯磺酸(50毫克,263微摩尔,0.23当量.)。反应液在15~20摄氏度下,搅拌3小时。LCMS检测到原料消耗完全,目标产物形成。反应液在5%的碳酸氢钠溶液(50毫升)和二氯甲烷(50毫升)分层。分离有机相,水相用二氯甲烷(50毫升)萃取2次。合并有机相,并用硫酸镁干燥,过滤,减压浓缩至干。经柱层析色谱纯化(二氧化硅,12%的乙酸乙酯在石油醚中),得到白色固体4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-碘-1-(四氢-2H-吡喃-2--1)-吲唑-5-羧酸叔丁酯(5-5)(564毫克,742微摩尔,66.0%产率,80%purity)。LCMS:(ESI)m/z=525.1[M+1-THP]+;1H NMR(400MHz,CDCl3)δ(ppm)7.46(d,1H),7.40(d,1H),6.97(t,2H),5.67(dd,1H),4.52-4.67(m,1H),3.95-4.03(m,1H),3.67-3.80(m,1H),3.05-3.16(m,2H),2.80(dd,2H),2.42-2.62(m,1H),2.04-2.27(m,6H),1.68-1.79(m,3H),1.27-1.44(m,9H)
步骤6:平行投两个反应:叔丁基4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-碘-1-(四氢-2H-吡喃-2--1)-吲唑-5-羧酸叔丁酯(5-5)(225毫克,370微摩尔,1.0当量.),1,4-二氧六环(5毫升)和磷酸钾(236毫克,1.11毫摩尔,3.01当量.)溶解在水(1毫升)中。反应液用氮气置换后,加入2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane(292毫克,1.16毫摩尔,50%in THF,3.15当量.)和[1,1-双(二叔丁基膦)二茂铁]二氯化钯(17毫克,26.1微摩尔,0.07当量.),氮气保护,反应在80摄氏度下搅拌2小时。LCMS检测到原料全部消耗,目标产物形成。冷却到20摄氏度,反应液在饱和食盐水(50毫升)和乙酸乙酯(50毫升)中分层,分离有机层,水相用乙酸乙酯(50毫升)萃取2次。合并有机相,硫酸镁干燥,过滤,减压浓缩至干。经柱层析色谱纯化(二氧化硅,0-5%-7%的乙酸乙酯在石油醚中),得到亮黄色油状脱碘的副产物4-(2,3-二氟-6,9-二氢-5H-苯并[7]环戊烯-7-基)-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-羧酸叔丁酯(5-1)(124毫克,257微摩尔,34.7%产率)和亮黄色油状目标产物叔丁基4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-甲基-1-(四氢-2H-吡喃-2--1)-吲唑-5-羧酸叔丁酯(5-6)(244毫克,442微摩尔,59.8%产率)。LCMS:(ESI)m/z=497.2[M+1]+;1H NMR(400MHz,CDCl3)δ(ppm)7.38(d,1H),7.33(d,1H),6.97(t,2H),5.60(dd,1H),4.02-4.09(m,1H),3.81-3.92(m,1H),3.68-3.78(m,1H),2.87-2.99(m,2H),2.80-2.87(m,2H),2.80(s,3H),2.48-2.61(m,1H),2.19-2.33(m,2H),2.06-2.18(m,3H),1.95-2.04(m,1H),1.70-1.84(m,2H),1.62-1.70(m,2H),1.58(s,9H)
步骤7:叔丁基4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-甲基-1-(四氢-2H-吡喃-2--1)-吲唑-5-羧酸叔丁酯(5-6)(239毫克,481微摩尔,1.0当量.)和四氢呋喃(8毫升)加入到反应瓶中。在15~2摄氏度下,加入四氢铝锂(1M四氢呋喃溶液,900uL,1.9当量.),反应液继续搅拌2小时。TLC检测到原料还在,新点形成。继续加入四氢铝锂(1M四氢呋喃,300uL,0.62当量.),在15-20摄氏度下,搅拌1小时。TLC(石油醚:乙酸乙酯=3:1)检测到大部分原料被消耗,新点形成。反应液用水(50mL)和15%的氢氧化钠溶液淬灭。反应用乙酸乙酯(50毫升)溶解,硫酸镁干燥,搅拌10分钟。过滤,减压浓缩干燥得到黄色固体粗产物(4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-甲基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-基)甲醇(5-7)(221毫克,518微摩尔,crude)。此粗产物无需进一步纯化,直接用于下一步反应。LCMS:(ESI)m/z=427.3[M+1]+;
步骤8:(4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-甲基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-基)甲醇(5-7)(210毫克,492微摩尔,1.0当量.)溶解在二氯甲烷(15毫升),加入二氧化锰(530毫克,6.10毫摩尔,12.4当量.).反应液在40摄氏度下搅拌3.5小时。过滤,减压浓缩得到类白色固体粗产物4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-甲基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-甲醛(5-8)(210毫克,495微摩尔)。此粗产物无需进一步纯化,直接用于下一步反应。LCMS:(ESI)m/z=425.1[M+1]+;
步骤9:4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-甲基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-甲醛(5-8)(204毫克,480微摩尔,1.0当量.),甲基(2-(甲基氨基)乙基)氨基甲酸叔丁酯(186毫克,987微摩尔,2.06当量.)和醋酸(62毫克,1.03毫摩尔,2.15当量.)溶解在二氯甲烷(3毫升),在25摄氏度下,搅拌2小时后,加入三乙氧羰基硼氢化钠(340毫克,1.60毫摩尔,3.34当量.)。反应液在25摄氏度下搅拌14小时。LCMS检测到原料被消耗,目标产物形成。反应液在5%碳酸氢钠(15毫升)溶液和二氯甲烷分层,分离有机相。水相用乙酸乙酯(10毫升)萃取3次。合并有机相,有硫酸镁干燥,过滤,减压浓缩至干,经柱层析色谱纯化(二氧化硅,30%的乙酸乙酯在二氯甲烷中),得到亮黄色油状物(2-((4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-甲基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-基)甲基)(甲基)氨基)乙基)(甲基)氨基甲酸叔丁酯(5-9)(204毫克,325微摩尔,67.6%产率)。LCMS:(ESI)m/z=597.4[M+1]+;
步骤10:盐酸-1,4二氧六环(4M,5毫升)加入到(2-((4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-甲基-1-(四氢-2H-吡喃-2-基)-1H-吲唑-5-基)甲基)(甲基)氨基)乙基)(甲基)氨基甲酸叔丁酯(5-9)(202毫克,338微摩尔,1.0当量.)的甲醇溶液中。反应液在10~15摄氏度下搅拌12小时。LCMS检测到原料消耗完全,目标产物形成。反应液减压浓缩至干。经反相经制备液相色谱纯化(YMC-ActusTriartC18柱,5um二氧化硅,30mm直径,150mm长度;使用水(含有0.05%氨水)和乙腈的极性递减的混合物作为洗脱液),得到白色固体N1-((4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-3-甲基-1H-吲唑-5-基)甲基-N1,N2-二甲基乙烷-1,2-二胺(P146,实施例5)(盐酸盐,105毫克,214微摩尔,63.3%产率,99%purity)。LCMS:(ESI)m/z=413.4[M+1]+;1H NMR(400MHz,CD3OD)tautomermixtureδ(ppm)7.84(d,0.5H),7.71(d,0.5H),7.49-7.55(m,1H),7.08-7.17(m,2H),4.74-4.84(m,1H),4.36-4.74(m,1H),4.08-4.20(m,0.5H),3.74-3.87(m,1.5H),3.63-3.72(m,1H),3.43-3.63(m,2H),3.29-3.37(m,1H)2.99-3.05(m,2H),2.96(s,1.5H),2.83-2.87(m,1H),2.83(s,1.5H),2.81(s,3H),2.74(s,1.5H),2.26(s,1.5H),2.09-2.26(m,2H),1.84-2.08(m,2H);19F NMR(376MHz,CD3OD)tautomer mixtureδ(ppm)-144.96,-145.32
实施例6:N1,N2-二甲基-N1-((3-(7-(三氟甲基)-4,5-二氢-1H-苯并[d]氮杂卓-3
(2H)-基)吡啶-2-基)甲基)乙烷-1,2-二胺(P088)的合成
化合物P088的合成参见实施例1,通过3-氟吡啶甲醛和中间体D进行合成。LCMS:(ESI)m/z=393.4[M+1]+;1H NMR(400MHz,D2O)δ(ppm)8.25(d,1H),7.91(d,1H),7.61(dd,1H),7.50(s,1H),7.47(d,1H),7.32(d,1H),4.24(s,2H),3.28-3.36(m,2H),3.15-3.20(m,2H),3.06-3.13(m,8H),2.71(s,3H),2.43(s,3H)
实施例7:N1-((4-(4,4-双(乙氧基甲基)环己基)-1H-吲唑-5-基)甲基)-N1,N2-二
甲基乙烷-1,2-二胺(P266)的合成
化合物P266的合成参见实施例4,通过中间体4-4和2-(4,4-双(乙氧基甲基)环己-1-烯-1-基)-4,4,5,5-四甲基-1,3,2-二氧杂硼烷进行合成。LCMS:(ESI)m/z=417.4[M+1]+;1H NMR(400MHz,D2O)δ(ppm)8.30(s,1H),7.52(d,1H),7.39(d,1H),4.60(s,2H),3.65(s,2H),3.62(q,J=7.03Hz,2H),3.58-3.65(m,2H),3.55(q,J=7.03Hz,2H),3.48-3.57(m,2H),3.30(s,2H),2.92-3.05(m,1H),2.82(s,3H),2.75(s,3H),1.97-2.14(m,2H),1.63-1.75(m,2H),1.48-1.58(m,2H),1.33-1.46(m,2H),1.20(t,J=7.03Hz,3H),1.16(t,J=7.03Hz,3H)
实施例8:N1-((4-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基)-1H-吲唑-
5-基)甲基)-N1,N2-二甲基乙烷-1,2-二胺(P167)的合成
化合物P167合成参见实施例4,通过中间体4-5和中间体A制备。LCMS:(ESI)m/z=399.2[M+1]+;1H NMR(400MHz,D2O)δ(ppm)8.05(s,1H),7.56(d,1H),7.45(d,1H),7.05(t,2H),4.71(s,2H),3.65-3.78(m,2H),3.54-3.63(m,2H),3.39-3.52(m,1H),2.95-3.08(m,2H),2.90(s,3H),2.75-2.85(m,2H),2.80(s,3H)1.88-2.12(m,4H)
实施例9:N1-((6-氨基-2-(4,4-双(乙氧基甲基)环己基)吡啶-3-基)甲基)-N1,N2-二甲基乙烷-1,2-二胺(P293)的合成
化合物P293制备方法参见实施例3合成方法,通过中间体3-2和2-(4,4-双(乙氧基甲基)环己-1-烯-1-基)-4,4,5,5-四甲基-1,3,2-二氧杂硼烷制备。LCMS:(ESI)m/z=393.3[M+1]+;1H NMR(400MHz,CD3OD)δ(ppm)8.41(s,2H),7.61(d,1H),6.57(d,1H),3.56(s,2H),3.54(q,J=7.00Hz,2H),3.49(s,2H),3.48(q,J=7.00Hz,2H),3.24(s,2H),3.10-3.16(m,2H),2.87-2.98(m,1H),2.67-2.71(m,2H),2.67(s,3H),2.24(s,3H),1.81-1.91(m,2H),1.74-1.81(m,2H),1.50-1.62(m,2H),1.33-1.44(m,2H),1.20(t,J=7.00Hz,2H),1.18(t,J=7.00Hz,2H)
实施例10:N1-((2-(2,3-二氟-6,7,8,9-四氢-5H-苯并[7]环戊烯-7-基-6-甲基吡
啶-3-基)甲基)-N1,N2-二甲基乙烷-1,2-二胺(P038)的合成
化合物P038采用实施例2合成方法,通过中间体2-2和中间体A制备。LCMS:(ESI)m/z=374.2[M+1]+;1H NMR(400MHz,D2O)δ(ppm)8.49(d,1H),7.73(d,1H),7.07(t,2H),4.61(s,2H),3.57-3.70(m,3H),3.48-3.56(m,2H),2.92-3.06(m,2H),2.81-2.89(m,2H),2.78(s,3H),2.77(s,3H),2.70(s,3H),2.01-2.13(m,2H),1.74-1.91(m,2H)
采用与上述类似的方法,制备得到化合物P001-P335,其表征数据见右栏:
生物测试例
测试例1 PRMT1酶活测试方法
PRMT1酶活测试实验在当天制备的缓冲液中进行,该缓冲液由10mM Tirs-HCl(pH=8.0),0.01%Tween-20和1mM DTT组成。用100%DMSO将化合物制备成100X反应中最终所需的最高抑制剂浓度,然后转移至384孔Echo板(符合Echo资格的384孔聚丙烯微板2.0,透明,平底)中的一个孔中并依次用100%DMSO的3倍稀释液进行稀释在下一个孔中,依此类推,以Precision计总共10个浓度。将100%DMSO添加到两个空孔中,作为同一384孔Echo板中没有化合物对照孔和没有酶的对照孔。通过Echo 550液体处理器将250nL的化合物从384孔Echo板的每个孔转移到384孔测定板(384孔聚丙烯储存微板)。对于有化合物和没有化合物的对照孔,将包含PRMT1酶的混合物(15uL)添加到384孔测定板中。对于没有酶的对照孔,则改为添加含有试验缓冲液的混合物(15uL)。使化合物与PRMT1在室温下孵育15分钟,然后加入含有3H-SAM和肽的混合物(10uL)以开始反应(最终体积=25uL)。组分的最终浓度如下:PRMT1为0.5nM,3H-SAM为0.25uM,肽为0.1uM,DMSO浓度为1%。孵育120分钟后,通过添加非放射性标记的SAM(5uL)至终浓度125uM终止测定,这将3H-SAM稀释至不再检测到其掺入肽底物的水平。然后将384孔测定板中的25μL反应液转移到384孔检测板(链霉亲和素FlashPlate HTS PLUS,高容量,384孔)中。在室温下,使生物素化的肽结合至抗生蛋白链菌素表面至少60分钟。然后在BioTek洗板机中将Flashplate用0.1%Tween-20洗涤3次。在微孔板计数器(MicroBeta2)上读板,以测量与检测板表面结合的3H标记的肽的量,以每分钟计数(cpm)测量。
曲线拟合:
从Reader拷贝原始数据,通过方程式(1)在Excel中计算抑制率数值,方程式(1):Inh%=(CPMmax-CPMcmpd)/(CPMmax-CPMmin)*100;Max信号通过酶与底物作用得到,Min信号通过底物得到。使用Excel中45.4.0.8版本XLFit插件通过方程式(2)拟合数据得到IC50值。方程式(2):Y=Bottom+(Top-Bottom)/(1+((IC50/X)*HillSlope)),其中,Y代表抑制百分率,X代表化合物浓度。
测试例2 Toledo细胞增殖抑制实验方法
A.目的:通过六天的细胞增殖实验来确定化合物对Toledo细胞的作用
B.试剂和材料:
1.细胞培养基:RPMI 1640+10%FBS
2.384孔细胞培养板(康宁,货号#3764)
3.0.4%台盼蓝染色液(赛默飞,货号#T10282)
4.细胞计数板(赛默飞,货号#C10228)
5.50ml试剂储液器(康宁,货号#4870)
6.50ml锥形无菌聚丙烯离心管(赛默飞,货号#339653)
7.自动细胞计数仪(赛默飞,货号#AMQAX1000)
8.CellTiter-Glo发光细胞活力检测试剂(普洛麦格,货号#G7572)
9.SpectraMax i3x多模式酶标仪(美谷分子仪器,货号#5024062)
C.实验方法
1.用移液管将细胞进行重悬
2.将0.4%台盼蓝染色液和Toledo细胞等比例混匀,用自动细胞计数仪对细胞进行计数
3.将Toledo细胞稀释到最终浓度每个孔2000个细胞,转移到50ml的试剂储液器中
4.将稀释好的Toledo细胞加入到384孔细胞培养板中,每个孔40ul
5.短暂离心沉降细胞
6.将细胞培养在37℃,5%CO2的细胞培养箱中
7.将CellTiter-Glo发光细胞活力检测试剂中的底物与溶液混匀
8.六天后从培养箱中取出384孔细胞培养板,每个孔加入20ul配置好的CellTiter-Glo试剂
9.将384孔细胞培养板放在轨道振动器中混匀30分钟
10.用SpectraMax i3x多模式酶标仪检测发光的信号
结果如下表中所示。其中,PRMT1酶活实验结果:
A代表IC50<50nM;
B代表50nM<=IC50<500nM;
C代表IC50>=500nM
Toledo细胞增殖抑制实验结果:
A代表IC50<1uM;
B代表1uM<=IC50<5uM;
C代表IC50>=5uM
PRMT1酶活测试和Toledo细胞增殖抑制测试结果如下表中所示:
测试例3 PRMT panel选择性测试
PRMT1的测试方法如测试例1,PRMT5、PRMT7测试与曲线拟合参考PRMT1测试与数据处理方法采用优化后参数进行。PRMT3的测试方法如下:
PRMT3实验方法:
这一实验在当天制备的缓冲液中进行测定,该缓冲液由10mM Tirs-HCl(pH=8.0),0.01%Tween-20和1mM DTT组成。用100%DMSO将化合物制备成100X反应中最终所需的最高抑制剂浓度,然后转移至384孔Echo板(符合Echo资格的384孔聚丙烯微板2.0,透明,平底)中的一个孔中并依次用100%DMSO的3倍稀释液进行稀释在下一个孔中,依此类推,以Precision计总共10个浓度。将100%DMSO添加到两个空孔中,作为同一384孔Echo板中没有化合物的对照孔和没有酶的对照孔。通过Echo 550液体处理器将100nL的化合物从384孔Echo板的每个孔转移到384孔测定板(OptiPlate(384-well,white))。对于有化合物的孔和没有化合物的对照孔,将包含PRMT1酶的混合物(5uL)添加到384孔测定板中。对于没有酶的对照孔,则改为添加含有试验缓冲液的混合物(5uL)。使化合物与PRMT3在室温下孵育15分钟,然后加入含有冷的SAM和肽的混合物(5uL)以开始反应(最终体积=10uL)。组分的最终浓度如下:PRMT3为0.1nM,SAM为15uM,肽为0.05uM,DMSO浓度为1%。室温孵育60分钟后,通过添加用AlphaLISA表观遗传学缓冲液稀释至终浓度10ug/mL的供体磁珠和受体磁珠(15uL)终止反应。将384孔测定板室温孵育60min,接下来用Alpha模式(Ex680/Em615)的多模式读板机测定相对荧光单位(RFU)。
曲线拟合:从Reader拷贝原始数据,通过方程式(1)在Excel中计算抑制率数值。方程式(1):Inh%=(RFUmax-RFUcmpd)/(RFUmax-RFUmin)*100,其中Max信号通过酶与底物作用得到,Min信号通过底物得到。使用Excel中45.4.0.8版本XLFit插件通过方程式(2)拟合数据得到IC50值。方程式(2):Y=Bottom+(Top-Bottom)/(1+((IC50/X)*HillSlope)),其中Y代表抑制百分率,X代表化合物浓度。
PRMT4,PRMT6,PRMT8测试与曲线拟合参考PRMT3测试与数据处理方法采用优化后参数进行。
下表中显示了PRMT panel选择性测试结果,其中A代表IC50<50nM;
B代表50nM<=IC50<500nM;
C代表IC50>=10uM
化合物 | PRMT3 | PRMT4 | PRMT5 | PRMT6 | PRMT7 | PRMT8 |
P207 | B | A | C | A | C | A |
P023 | A | A | C | A | C | A |
P118 | B | B | C | A | C | A |
测试例4 RKO in cell western实验方法
将RKO以20000细胞/ml的浓度种到多聚赖氨酸包被过的96孔板(Corning#3599)中,每孔铺2000个细胞及100μL培养基。将500nL化合物加入96孔板中。3)将96孔板放入37℃,5%二氧化碳恒温培养箱中培养72小时。三天后将96孔板从恒温培养箱中取出,每孔加入100μL 8%多聚甲醛溶液,室温放置15分钟。15分钟,甩出板中液体,并用磷酸盐缓冲液(1*PBS)清洗三次。甩出板中液体,加入200μL破膜缓冲液(PBS中加入0.1%(v/v)吐温-20),在摇床上孵育30分钟。半个小时后甩出板中液体,加入封闭缓冲液,在室温摇晃孵育两个小时。之后甩干板中液体,将含一抗的的封闭液(MMA一抗,CST#8711S,1:1000v/v)加入96孔板中,4℃摇晃过夜孵育。第二天用清洗液(PBS中加入0.05%(v/v)吐温-20)清洗三次,加入含二抗的封闭液(山羊抗兔IgG(H+L)Invitrogen#31460,1:10000v/v),室温孵育两个小时。之后用清洗液清洗96孔板四次。将TMB混合液加入96孔板中,室温摇晃孵育15分钟。之后,加入反应终止液,用酶标仪读取OD450nm。用清洗液清洗三次,加入50μL健那绿染液,室温摇晃孵育15分钟。清水清洗十次至无色残留,每孔加入200μL 0.5M盐酸溶液,室温孵育10分钟。使用Flexstation在OD595nm处读值。
计算:
首先计算每个孔的比值OD450/OD595
每块板有6个DMSO阴性对照组(ZPE)和6个10μM的阳性对照组(HPE),用对照组比值的平均值来确定每个测试孔的激活百分比。待测化合物用DMSO进行三倍稀释,一共8个浓度点,起始浓度5μM。每个测试孔的激活百分比的计算公式:
激活百分比=100-[(HPE比值-某一孔比值)/(HPE比值-ZPE比值)]*100
表4 RKO ICW实验结果
A代表EC30<250nM
B代表250nM<=EC30<2500nM
C代表EC30>2500nM
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (13)
1.一种如下式I所示的化合物,或其药学上可接受的盐或氘代产物:
X1、X2、X3和X4各自独立地选自下组:CR、NR或N;虚线为化学键或无;
A环选自下组:取代或未取代的饱和或部分不饱和(非芳香)的4-8元碳环、取代或未取代的饱和或部分不饱和(非芳香)的4-8元杂环;
B环选自下组:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳环、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的3-12元的杂环、取代或未取代的-C1-C6烷基-6-10元芳基、取代或未取代的C3-C12碳环、取代或未取代的C2-C10酰基、取代或未取代的C2-C10酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
m和n各自独立地选自下组:0、1、2、3、4、5或6;
L选自下组:化学键,或-O-、-(CHR6)p-、-CHR6-O-、-CHR6-C(O)-、羰基、S、-NH-、-NHC(O)-、-NHS(O)2-、-NHC(O)NH-、-NHC(S)NH-、-COO-、-O-S(O)2-、-COO-CH2-、-C(O)CH2-、-S(O)2-,或L不存在;
p选自下组:1、2或3;
R1和R2各自独立地选自下组:H、取代或未取代的C1-C6烷基、取代或未取代的C3-C6环烷基;
R3为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C12碳环、取代或未取代的C2-C10酰基、取代或未取代的C2-C10酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
R为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的4-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C12碳环、取代或未取代的C2-C10酰基、取代或未取代的C2-C10酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
或两个位于相邻环原子上的R与其相连的环原子共同构成取代或未取代的5-11元碳环或杂环,所述的环为部分不饱和或饱和的;较佳地,所述的碳环或杂环为5-9元碳环或杂环,更优选为5-7元碳环或杂环(所述的碳环或杂环为饱和、部分不饱和或芳香性的);
R4为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C12碳环、取代或未取代的C2-C10酰基、取代或未取代的C2-C10酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
或两个位于相同或相邻环原子上的R4与其相连的环原子共同构成取代或未取代的3-11元碳环或杂环,所述的环为部分不饱和环、饱和环或芳香性环;
R6为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、酰基磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基;
除非特别说明,上述各式中,所述的取代指对应基团上的氢原子被一个或多个选自下组的取代基所取代:氘、氚、卤素、羟基、羧基、巯基、苄基、氧(=O)、C1-C12烷氧基羰基、C1-C6醛基、氨基、C1-C6酰胺基、硝基、氰基、未取代或卤代的C1-C6烷基、C2-C10烯基、C1-C6烷氧基、C1-C6烷基-胺基、C1-C6烷基-S-、C6-C10芳基、五元或六元杂芳基、五元或六元非芳香性杂环基、-O-(C6-C10芳基)、-O-(五元或六元杂芳基)、-NH-(C6-C10芳基)、-NH-(五元或六元杂芳基)、C1-C12烷氨基羰基、未取代或卤代的C2-C10酰基、磺酰基(-SO2-OH)、磷酰基(-PO3-OH)、未取代或卤代的C1-C4烷基-S(O)2-、未取代或卤代C1-C4烷基-SO-;各式中,杂环或杂芳环中具有1-3个选自下组的杂原子:N、S或O;
所述的芳香环、芳香性环或芳香体系包括芳香环的常规互变异构体,如吡啶酮、苯并咪唑、苯并吡唑等。
在另一优选例中,X1、X2、X3和X4中至少一个为N。
在另一优选例中,当B环为H时,所述的m为2、3、4、5或6;且至少两个相同或相邻环原子上的R4与其相连的环原子共同构成取代或未取代的5-11元碳环或杂环(所述的环为部分不饱和环、饱和环或芳香性环)。
2.如权利要求1所述的化合物,或其药学上可接受的盐或氘代产物,其特征在于,所述的R3为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-10元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;和/或
R为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-10元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;或两个位于相邻环原子上的R与其相连的碳原子共同构成取代或未取代的5-9元碳环或杂环,所述的环为部分不饱和、饱和或芳香性的;和/或
在另一优选例中,R4为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-7元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C10酯基、取代或未取代的C6-C10芳氧基、取代或未取代的C1-C6酰胺基、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;或两个位于相邻环原子上的R4与其相连的碳原子共同构成取代或未取代的5-9元碳环或杂环,所述的环为部分不饱和或饱和的。
3.如权利要求1所述的化合物,或其药学上可接受的盐或氘代产物,其特征在于,所述的B环选自下组:H,或取代或未取代的苯基、取代或未取代的5-10元杂芳环、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的3-12元的杂环、取代或未取代的C3-C12碳环。
4.如权利要求1所述的化合物,或其药学上可接受的盐或氘代产物,其特征在于,所述的R3为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-10元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;和/或
R为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;或两个位于相邻环原子上的R与其相连的环原子共同构成取代或未取代的5-7元碳环或杂环;和/或
R4为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C10酯基、取代或未取代的C1-C6酰胺基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;或两个位于相邻环原子上的R4与其相连的碳原子共同构成取代或未取代的5-9元碳环或杂环,所述的环为部分不饱和或饱和的。
5.如权利要求1所述的化合物,或其药学上可接受的盐或氘代产物,其特征在于,所述的B环选自下组:取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的4-12元的杂环、取代或未取代的C3-C12碳环。
6.如权利要求1所述的化合物,或其药学上可接受的盐或氘代产物,其特征在于,所述的A环选自下组:
或所述的A环与2个R4共同构成选自下组的基团:
在另一优选例中,所述的A环为取代或未取代的选自下组的基团:
或所述的A环与2个R4共同构成选自取代或未取代的下组的基团:
8.如权利要求1所述的化合物,或其药学上可接受的盐或氘代产物,其特征在于,所述的化合物具有如下式III所示的结构:
其中,
A环选自下组:取代或未取代的饱和或部分不饱和(非芳香)的4-8元碳环、取代或未取代的饱和或部分不饱和(非芳香)的4-8元杂环;
B环选自下组:取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的3-12元的杂环、取代或未取代的C3-C12碳环;
较佳地,R3为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
较佳地,R4为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-7元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-。
9.如权利要求1所述的化合物,或其药学上可接受的盐或氘代产物,其特征在于,所述的化合物具有如下式IV所示的结构:
其中,
A1环选自下组:取代或未取代的饱和或部分不饱和(非芳香)的5-8元碳环、取代或未取代的饱和或部分不饱和(非芳香)的5-8元杂环;
A2环选自下组:取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的C3-C12碳环;且A2环和A1环稠合;
A3环和A4环各自独立地选自下组:取代或未取代的饱和或部分不饱和(非芳香)的5-8元碳环、取代或未取代的饱和或部分不饱和(非芳香)的3-8元杂环;
m为0、1、2、3或4;R5选自下组:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C6-C10芳氧基或杂芳氧基、取代或未取代的C6-C10芳胺基或杂芳胺基,取代或未取代的C1-C6酰胺基、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;且R5可以位于A1环、A2环、A3环或A4环上。
10.如权利要求1所述的化合物,或其药学上可接受的盐或氘代产物,其特征在于,所述的化合物具有如下式V或式VI所示的结构:
其中,C环为取代或未取代的苯基、取代或未取代的5-7元杂环基、或取代或未取代的5-6元杂芳基;
A环选自下组:取代或未取代的饱和或部分不饱和(非芳香)的5-6元碳环、取代或未取代的饱和或部分不饱和(非芳香)的4-8元杂环;
B环选自下组:取代或未取代的C6-C10芳基、取代或未取代的5-12元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的4-12元的杂环、取代或未取代的C3-C12碳环;
较佳地,R3为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-;
较佳地,R4为选自下组的基团:H、卤素、氰基、氨基、硝基、羟基、巯基、醛基、羧基、磺酰基、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基、取代或未取代的C1-C6烷胺基、取代或未取代的C6-C10芳基、取代或未取代的5-7元杂芳基、取代或未取代的含有1-3个选自氧、硫和氮中的杂原子的5-7元的杂环、取代或未取代的-C1-C6烷基-苯基、取代或未取代的C3-C8碳环、取代或未取代的C2-C6酰基、取代或未取代的C2-C6酯基、取代或未取代的C1-C4烷基-S(O)2-、取代或未取代的C1-C4烷基-SO-。
在另一优选例中,所述的C环选自下组:苯环、5-7元杂芳环、5-7元饱和或部分不饱和杂环。
在另一优选例中,所述的式I化合物具有如下式所示的结构:
X5、X6、X7和X8各自独立地选自下组:C(R)2、NR、CR或N;虚线为化学键或无。
12.一种药物组合物,其特征在于,所述的药物组合物含有治疗有效量的如权利要求1所述的式I化合物、或其可药用的盐,以及一种或多种可药用的载体、赋形剂、佐剂、辅料和/或稀释剂。
13.如权利要求1所述的式I化合物、或其可药用盐在制备治疗或预防与PRMT相关的疾病的药物组合物中的用途;较佳地,所述的PRMT为I型PRMT。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280036839.3A CN117377649A (zh) | 2021-05-21 | 2022-05-18 | 一类精氨酸甲基转移酶抑制剂及其用途 |
CA3219927A CA3219927A1 (en) | 2021-05-21 | 2022-05-18 | Arginine methyltransferase inhibitor and use thereof |
AU2022275898A AU2022275898A1 (en) | 2021-05-21 | 2022-05-18 | Arginine methyltransferase inhibitor and use thereof |
KR1020237044370A KR20240013180A (ko) | 2021-05-21 | 2022-05-18 | 아르기닌 메틸전달효소 억제제 및 이의 용도 |
PCT/CN2022/093688 WO2022242696A1 (zh) | 2021-05-21 | 2022-05-18 | 一类精氨酸甲基转移酶抑制剂及其用途 |
BR112023024167A BR112023024167A2 (pt) | 2021-05-21 | 2022-05-18 | Inibidor de arginina metiltransferase e uso do mesmo |
EP22804016.8A EP4342878A1 (en) | 2021-05-21 | 2022-05-18 | Arginine methyltransferase inhibitor and use thereof |
TW111118991A TW202313554A (zh) | 2021-05-21 | 2022-05-20 | 一類精胺酸甲基轉移酶抑制劑及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110560615X | 2021-05-21 | ||
CN202110560615 | 2021-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115368246A true CN115368246A (zh) | 2022-11-22 |
Family
ID=84060543
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110875453.9A Pending CN115368246A (zh) | 2021-05-21 | 2021-07-30 | 一类精氨酸甲基转移酶抑制剂及其用途 |
CN202280036839.3A Pending CN117377649A (zh) | 2021-05-21 | 2022-05-18 | 一类精氨酸甲基转移酶抑制剂及其用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280036839.3A Pending CN117377649A (zh) | 2021-05-21 | 2022-05-18 | 一类精氨酸甲基转移酶抑制剂及其用途 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4342878A1 (zh) |
KR (1) | KR20240013180A (zh) |
CN (2) | CN115368246A (zh) |
AU (1) | AU2022275898A1 (zh) |
BR (1) | BR112023024167A2 (zh) |
CA (1) | CA3219927A1 (zh) |
TW (1) | TW202313554A (zh) |
WO (1) | WO2022242696A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023156386A2 (en) * | 2022-02-16 | 2023-08-24 | Duke Street Bio Limited | Pharmaceutical compound |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04011093A (es) * | 2002-05-10 | 2005-02-14 | Neurocrine Biosciences Inc | Piperazina sustituida como ligandos de receptores de melanocortina. |
US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
WO2008104077A1 (en) * | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
CA2903264A1 (en) * | 2013-03-14 | 2014-11-06 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
US20170280720A1 (en) * | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
CN108947879B (zh) * | 2017-05-17 | 2022-06-28 | 中国科学院上海药物研究所 | Prmt i型抑制剂及其制备方法和用途 |
EP3802500A4 (en) * | 2018-06-05 | 2022-03-02 | Crinetics Pharmaceuticals, Inc. | MELANOCORTIN SUBTYPE 2 RECEPTOR (MC2R) ANTAGONISTS AND THEIR USES |
CN110845474B (zh) * | 2019-11-07 | 2021-01-12 | 四川大学 | 一种靶向i型prmt的化合物及其制备方法和应用 |
-
2021
- 2021-07-30 CN CN202110875453.9A patent/CN115368246A/zh active Pending
-
2022
- 2022-05-18 EP EP22804016.8A patent/EP4342878A1/en active Pending
- 2022-05-18 CN CN202280036839.3A patent/CN117377649A/zh active Pending
- 2022-05-18 KR KR1020237044370A patent/KR20240013180A/ko active Search and Examination
- 2022-05-18 WO PCT/CN2022/093688 patent/WO2022242696A1/zh active Application Filing
- 2022-05-18 CA CA3219927A patent/CA3219927A1/en active Pending
- 2022-05-18 BR BR112023024167A patent/BR112023024167A2/pt unknown
- 2022-05-18 AU AU2022275898A patent/AU2022275898A1/en active Pending
- 2022-05-20 TW TW111118991A patent/TW202313554A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP4342878A1 (en) | 2024-03-27 |
BR112023024167A2 (pt) | 2024-02-06 |
CA3219927A1 (en) | 2022-11-24 |
KR20240013180A (ko) | 2024-01-30 |
WO2022242696A1 (zh) | 2022-11-24 |
AU2022275898A1 (en) | 2024-01-18 |
CN117377649A (zh) | 2024-01-09 |
TW202313554A (zh) | 2023-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2719428C2 (ru) | Индазольные соединения в качестве ингибиторов киназы fgfr, их получение и применение | |
CN110573501B (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
CN112608318B (zh) | 一种作为蛋白质激酶抑制剂的化合物及其用途 | |
CN108314677B (zh) | 一种ezh2抑制剂及其用途 | |
EP3675860B1 (en) | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | |
EP3604306A1 (en) | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | |
AU2016272258A1 (en) | Pyrido(3,4-d)pyrimidine derivative and pharmaceutically acceptable salt thereof | |
KR20220028072A (ko) | Bet 억제제로서의 헤테로시클릭 화합물 | |
CN113135910A (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
RU2734959C2 (ru) | Трициклические конденсированные производные пиридин-2-она и их применение в качестве ингибиторов brd4 | |
CN113330009B (zh) | 氮杂环化合物、其制备方法及用途 | |
EP3481824B1 (en) | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
EP2015748B1 (en) | A C-Kit kinase inhibitor for use in the treatment of gastrointestinal stromal tumor or mastocytosis | |
US20210040066A1 (en) | Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof | |
CN118055933A (zh) | 选择性parp1抑制剂及其应用 | |
CN113968856B (zh) | 一类具有激酶抑制活性的化合物 | |
CN115368246A (zh) | 一类精氨酸甲基转移酶抑制剂及其用途 | |
WO2017118438A1 (zh) | 作为fgfr抑制剂的杂环化合物 | |
US20220289719A1 (en) | Heterocyclic compounds as mnk inhibitors | |
CN112538084B (zh) | 新颖的kras g12c蛋白抑制剂及其制备方法和用途 | |
CN111848605B (zh) | 一种取代吡啶并[3,4-b]吡嗪-2(1H)-酮化合物、其制备方法和用途 | |
CN112574255B (zh) | 一类基于有机胂的cdk抑制剂及其制备方法和用途 | |
CN116888107A (zh) | 作为Wee-1抑制剂的稠环化合物 | |
JP2024521741A (ja) | アルギニンメチルトランスフェラーゼ阻害剤およびその用途 | |
CN114805375B (zh) | 一种n-苯基烷氧基二苯并吖庚因类化合物、其制备方法及医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |